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Numerous studies have implicated an inflammatory link between obesity and 
type 2 diabetes. While inflammation is highly correlated with increases in adiposity, the 
role played by inflammation in the manifestations of obesity remains unclear. We 
applied a multidisciplinary approach spanning from in vivo animal physiology to in vitro 
cell culture and biochemistry to address the role of obesity-related inflammation in 
adipose tissue. 
 The inhibitor of κB kinase β (IKKβ) has previously been linked to insulin 
resistance. High-fat diet dramatically increased protein and kinase activity levels of the 
two noncanonical IKK family members, IKKε and TBK1, in adipose tissue. Genetic 
ablation of IKKε or pharmacologic inhibition of IKKε and TBK1, using the selective 
protein kinase inhibitor amlexanox, resulted in many metabolic improvements, including 
reduced weight gain in mice on a high fat diet. The improvements in IKKε knockout and 
amlexanox-treated mice on a high fat diet were correlated with increased energy 
expenditure, core body temperature, adipogenesis, and the proton uncoupling protein, 
UCP1 protein levels in adipose tissue. 
Inhibitors of IKKε and TBK1 that are structurally unrelated to amlexanox 




accumulation and adipocyte proliferation in 3T3-L1 adipocytes. Increased adipogenesis 
in response to IKKε and TBK1 inhibitors paralleled the adipocyte hyperplasia seen in 
the IKKε knockout mouse. Ex vivo stimulation of white adipose tissue from IKKε 
knockout mice with the adenylyl cyclase activator forskolin, resulted in increased 
glycerol release and lipolytic signaling compared to white adipose tissue from wild type 
mice. Moreover, treating 3T3-L1 adipocytes with amlexanox increased lipolysis in a 
dose-dependent manner and increased oxygen consumption to the same degree that 
forskolin does. These studies suggested that IKKε and TBK1 attenuate cAMP-
dependent processes in adipocytes to regulate energy expenditure. 
Further studies with 3T3-L1 adipocytes elucidated the mechanism by which IKKε 
and TBK1 regulate cAMP and β-adrenergic signaling in 3T3-L1 adipocytes. Expression 
of IKKε in 3T3-L1 adipocytes decreased UCP1 expression in response to β-adrenergic 
stimulation. The rate of lipolysis, levels of cAMP, and phosphorylation of PKA substrates 
such as hormone sensitive lipase (HSL) were also diminished in response to 
isoproterenol or forskolin by overexpression of IKKε or TBK1 in 3T3-L1 adipocytes. IKKε 
and TBK1 are induced by inflammatory stimuli, such as tumor necrosis α (TNFα) and 
Poly(I:C), and blockade of these kinases reversed the diminution of β-adrenergic 
signaling, cAMP, and lipolysis. The reduction of cAMP levels in 3T3-L1 adipocytes 
expressing IKKε or TBK1 was reversed by the phosphodiesterase 3B inhibitor, 
zardaverine. IKKε and TBK1 were found to bind to and phosphorylate PDE3B at serine 
318, resulting in its activation and 14-3-3β binding. These studies suggest that reduced 
cAMP production through phosphorylation and activation of PDE3B by IKKε and TBK1 




Chapter I:  
Introduction 
Obesity Epidemiology 
Obesity is a central feature of a vast array of diseases including type 2 diabetes, 
atherosclerosis, asthma, and cancer (1), and its increasing prevalence has defined a 
new epidemic in human history (2). Whereas “overweight” technically refers to excess 
body weight and “obese” refers to excess body fat, these terms have been adapted into 
body mass index (BMI) categories, for which there are mathematical definitions. BMI is 
measured as body weight (in kg) divided by height squared (in meters2). The World 
Health Organization and National Heart, Lung, and Blood Institute define overweight as 
a BMI greater than 25, but less than 30, while obesity is defined as a BMI of greater 
than 30 kg/m2  (3). While the worldwide prevalence of obesity is 12% (2), the United 
States has the highest rate of obesity for developed countries with 35.6% of the 
population in 2010 (4). Given its prevalence and health implications, understanding the 
pathogenesis of obesity is critical to improve human health. 
The factors that contribute to adult obesity can occur at any age, and 
environmental contributions to obesity exist throughout life. Prenatal contributions to 
obesity may include maternal smoking (5) as well as maternal type 2 diabetes and 




reduced risk of childhood (7) and adult (8) obesity. While adiposity very early in 
childhood is not a good predictor of adult obesity, adiposity from age 5 onwards is a 
significant risk factor for obesity (9). Therefore, early negative influences disadvantage 
children by increasing the likelihood of obesity and its comorbidities later in life. 
Beyond childhood, overnutrition and a sedentary lifestyle are the main 
contributing factors to obesity, and fluctuations in these factors result in weight changes 
through life (10). Increased food supplies and food consumption may be partly 
responsible for the rising prevalence of obesity (11). It has been reported in western 
society that reduced energy expenditure contributes more heavily to modern obesity 
than overnutrition (10). The contribution of decreased energy expenditure to obesity is 
important to highlight, because many of the studies performed in this thesis address 
defects in energy expenditure and potential therapeutic targets to alter energy 
expenditure and prevent obesity. 
Energy Expenditure in Obesity 
In its simplest form, weight gain results from an imbalance between energy 
intake and energy expenditure. Total energy expenditure can be broken into obligatory 
energy expenditure (OEE), energy expenditure due to physical activity, and adaptive 
thermogenesis (12). OEE can be summarized as the energy required for the 
performance of cellular and organ functions. Variations of this term converge on a 
measure of energy expenditure during an unstressed, resting state of an animal. 
Physical activity-related energy expenditure is inherently variable and it depends mostly 
on the type and intensity of activity. Adaptive thermogenesis is also variable but, similar 




system. Perturbations in any of these components of energy expenditure can therefore 
affect body weight, but “with few exceptions, most rodent models of obesity have 
defects in adaptive thermogenesis” (12). 
Adaptive thermogenesis is a homeostatic process regulated by the 
hypothalamus, which increases brown adipose tissue (BAT) thermogenic activity in 
response to decreased temperature as well as in response to diet (13). In cold-induced 
thermogenesis, hypothalamic integration of low temperature signals leads acutely to 
heat generated through shivering. In addition to shivering, chronic cold exposure 
recruits nonshivering thermogenesis by activating BAT to maintain homeothermy. Diet 
regulates adaptive thermogenesis both immediately after eating as well as chronically 
through signals from energy reserves. A single meal leads to a significant, transient 
increase in metabolism in BAT due to elevated plasma insulin and glucose uptake, 
known as “postprandial thermogenesis” (14). Increases in the ability to generate heat 
due to excess energy reserves over time are known as “diet-induced thermogenesis.” 
This effect is mediated mostly by leptin, secreted from white adipose depots, which acts 
at the hypothalamus to indicate energy excess and then signal BAT to increase activity, 
which balances energy homeostasis (15). 
Both cold-induced and dietary thermogenesis are homeostatic mechanisms in 
BAT to maintain different set points, but through a similar mechanism of uncoupling the 
electron transport chain from ATP synthesis. Uncoupling protein 1 (UCP1), also known 
as thermogenin, is found on the inner mitochondrial membrane where it dissipates the 
mitochondrial proton gradient to generate heat, which is largely responsible for adaptive 




sympathetic chain, activates β-adrenergic receptors in BAT to initiate a cascade of 
events through protein kinase A (PKA) culminating in the transcriptional up-regulation of 
UCP1 as well as post-transcriptional UCP1 activation by liberated free fatty acids (16). 
Brown fat, therefore, plays a prominent role in adaptive thermogenesis using UCP1. 
Since thermogenic capacity is almost entirely attributed to UCP1, any reference to BAT 
thermogenic function is a reference to UCP1 activity, even when that thermogenic 






Figure 1.1: Schematic of Energy Expenditure: OEE, physical activity, and 
adaptive thermogenesis. Whereas obligatory energy expenditure is constant, physical 
activity and adaptive thermogenesis are variable. Adaptive thermogenesis depends on 









Lipolytic Pathway in Adipose Tissue 
Lipolysis is the liberation of free fatty acids from triglycerides in adipose tissue 
and occurs through several different mechanisms. Lipolysis may occur extracellularly in 
vascular beds mediated by lipoprotein lipase (LPL) (17). Intracellular lipolysis is 
increased through the action of the mitogen-activated protein kinase (MAPK) signaling 
pathways or through the cyclic nucleotides, cAMP and cGMP (18, 19). Other forms of 
intracellular lipolysis depend on breakdown of lipid droplet-forming machinery, including 
downregulation of peroxisome proliferator-activated receptor-γ (PPARγ) (20). Hormonal 
regulation of cyclic nucleotide levels in adipocytes is partly regulated by natriuretic 
peptides (21), whose receptors have intrinsic guanylyl cyclase catalytic activity; 
however, cAMP levels are mainly regulated by insulin and catecholamines (13). 
Obese subjects have reduced whole-body adrenergic stimulated lipolysis (22-
25). Desensitization to catecholamines is seen in both muscle and adipose tissue (23, 
24). Adipocytes cultured from obese individuals have a dramatic reduction in 
isoproterenol- or norepinephrine-induced lipolysis (26, 27).  Infusion of epinephrine was 
able to increase plasma fatty acid flux and oxidation in lean subjects while plasma free 
fatty acid levels were unchanged in obese subjects (22, 23).  
Studies of obese children with impaired responses to adrenergic stimuli suggest 
catecholamine resistance is a primary defect in obesity (28, 29). Reduced 
catecholamine-induced lipolysis in adipose tissue does not improve after weight 
reduction (24). Impaired lipolysis is a characteristic of obesity in childhood (28, 29), and 




suggesting a role of genetics or early environmental factors in reduced lipolytic 
responses.  
Mouse knockout models of the lipolytic machinery, observations from adipose 
tissue from obese subjects, and polymorphisms of mediators of lipolysis have allowed 
the field to further investigate the roles of these proteins in lipolysis and whole body 
metabolism.  
Adrenergic Receptors, Heterotrimeric G-proteins, and Adenylyl Cyclase 
Catecholamines bind adrenergic receptors, which are seven α-helix 
transmembrane receptors, and their functions have been extensively studied (13). 
These receptors are broken into α1,2 and β1-3 subtypes that differ in their affinity for 
catecholamines, tissue distribution, pharmacologic agonists and antagonists, and 
mechanism of action. Unlike the natriuretic peptide receptor that has guanylyl cyclase 
activity, α and β adrenergic receptors are coupled to heterotrimeric G-proteins. 
Heterotrimeric G-proteins are made up of a Gα subunit and a βγ complex. When 
catecholamines bind to α or β adrenergic receptors, the receptor acts as a guanine 
nucleotide exchange factor for Gα, promoting GTP to replace GDP, which results in Gα 
activation and the separation of the βγ complex from Gα. The main role of Gα is to 
modulate the conversion of ATP to cyclic AMP by adenylyl cyclase. 
 In adipocytes, Gα can be either stimulatory (Gs) or inhibitory (Gi) toward adenylyl 
cyclase activity (31). All three β-adrenergic receptors are coupled to Gs to promote 
lipolysis in adipose tissue. Whereas β1,2 receptors are mostly responsible for hormonal 




(32). In contrast to β-adrenergic receptors, α2-adrenergic receptors in adipocytes are 
coupled to Gi subunits which serve to inhibit lipolysis in adipose tissue (33). However 
the net effect of adrenergic stimuli predominantly is to increase in cAMP in adipocytes.  
Adrenergic receptors are coupled to Gα to affect adenylyl cyclase activity in the 
production of cAMP (13). There are ten known adenylyl cyclase isoforms in mammals. 
Most isoforms of adenylyl cyclase are activated by Gs, and are pharmacologically 
stimulated by forskolin, whereas Gi works only on adenylyl cyclase types I, V, and VI 
(34). Mature adipocytes have significantly higher type V and VI adenylyl cyclase 
transcript levels than preadipocytes, suggesting that these isoforms may play a 
significant role in both stimulatory and inhibitory regulation of cAMP in adipocyte 
function (35). 
In obesity, the desensitization of adrenergic stimulation in fat has been partly 
attributed to decreased levels of β2-adrenergic receptors (36). Studies of polymorphisms 
in the lipolytic pathways suggest that obesity and resistance to catecholamine-induced 
lipolysis are linked.  The β2-adrenergic receptor has several polymorphisms that have 
aberrant signaling, and these have been correlated with defects in catecholamine-
induced signaling both in cell culture (37, 38) and in the context of obesity (39), 
including blunted in vivo lipolysis and fatty acid oxidation (40). The β1-3-adrenergic 
receptor triple knockout mice are obese on a normal diet and are cold intolerant (41), 
which I will discuss later. Along with decreases in β-adrenergic receptor levels, 
activation of α2-receptors in obese adipose tissue after exercise has also been observed 




attenuated in obese adipose tissue. Reduced receptor levels lead to impaired cAMP 
production, resulting in decreased PKA activity.  
Cyclic Adenosine Monophosphate (cAMP) 
cAMP was the first “second messenger” discovered, and its action in adipocytes 
has been studied extensively (13). cAMP is known to stimulate protein kinase A, which 
subsequently phosphorylates downstream substrates. cAMP also stimulates Epac, a 
guanine nucleotide exchange factor for the Rap subfamily of small GTPases (42). Both 
the regulatory subunit of PKA and Epac have regulatory cyclic AMP-binding domains, 
and PKA and Epac act independently, synergistically, and antagonistically toward each 
other. Epac activates AMPK to improve adipocyte lipid and energy metabolism in mice 
(43), and Epac also plays a role in adipocyte differentiation (44). While the role of Epac 
in adipocyte development and metabolism continues to be elucidated, the role of PKA in 
adipocyte function has been studied for over 30 years.  Co-incubation of adipocytes with 
the PKA inhibitor H89 results in a near-total ablation of lipolysis induced by 
isoproterenol (45). Surprisingly, few, if any, polymorphisms in PKA or Epac have been 
identified in the study of obesity, despite their essential roles in β-adrenergic signaling.  
Lipases and Associated Proteins 
The hydrolysis of triglycerides into three fatty acids and glycerol is performed by 
the coordinated action of three lipases: adipose triglyceride lipase (ATGL), hormone 
sensitive lipase (HSL), and monoglyceride lipase (MGL). Beyond the receptor, 





Adipose Triglyceride Lipase (ATGL) 
Activation of ATGL, a process not directly attributed to PKA (46), facilitates the 
conversion of triglycerides to diacylglycerides (DAG). A triglyceride hydrolase activator 
first identified in C. elegans, CGI-58, increases ATGL activity up to 20 fold (47). CGI-58 
can reversibly bind the lipid droplet associated protein, perilipin, in a PKA-dependent 
manner (48, 49). Therefore, a combination of PKA-dependent and independent 
mechanisms regulate ATGL action. 
ATGL knockout mice have increased body weight and fat mass, and decreased 
catecholamine-induced lipolysis (50). Absence of ATGL results in defective lipolysis and 
cold adaptation, due to reduced accessibility of fatty acids. Subjects with loss-of-
function mutations in ATGL (51) and CGI-58 (47) have lipid storage diseases, which 
result in adiposity in multiple organs and reduced adipose tissue lipid storage. 
Furthermore, 12 ATGL polymorphisms have been associated with significant deviations 
of plasma free fatty acids, triglycerides, glucose, and risk of type 2 diabetes (52). 
However, studies have not reported reduced catecholamine-induced lipolysis in either 
ATGL or CGI-58 defective subjects, and the implications of ATGL activity in human 
physiology are largely unknown. 
Hormone Sensitive Lipase (HSL) and Perilipin 
Together, ATGL and HSL combine to account for greater than 95% of triglyceride 
hydrolysis in mouse adipose tissue (53, 54). While ATGL prevails in basal lipolysis, HSL 
plays a predominant role in catecholamine-stimulated lipolysis.  Once cAMP is 
produced, PKA phosphorylates perilipin, which allows access of lipases to the lipid 




HSL phosphorylation promotes the association of HSL with lipid droplets to hydrolyze 
diacylglycerol (and triacylglycerol at times) (60).  Lipotransin is another lipid droplet 
protein that translocates HSL to lipid droplets (61). While PKA action accounts for a 
large percentage (80%) of catecholamine-induced lipolysis, MAPK signaling pathways 
also mediate a minor portion (20%) of lipolysis by phosphorylating HSL (18).  
Reduced expression of HSL has been observed in adipose tissue of obese 
subjects (62, 63), and a catalytically deficient form of HSL has also been observed in 
obese adipose tissue (64). HSL knockout mice are lean despite the inability to respond 
to β-adrenergic stimuli. Conflicting reports of insulin sensitivity have been made in HSL 
knockout mice (65-68). HSL is decreased in both expression and activity of first degree 
relatives of obese subjects, suggesting heritability or early environmental influences of 
HSL in obesity (30). A -60C/G polymorphism within the HSL promoter decreases 
expression of HSL in cell culture by 40% (69) and plays a role in body fat composition 
(70). Another polymorphism in an intronic region of the HSL gene is associated with 
obesity and decreased catecholamine-induced lipolysis (71-73).  
Polymorphisms in perilipin are associated with obesity-related phenotypes and 
impaired ability to lose weight (74, 75). One such polymorphism, in intron six of the 
perilipin gene, is associated with reduced perilipin protein levels as well as increased 
basal and catecholamine-induced lipolysis from adipocytes from obese subjects (74, 
75). Perilipin knockout mice have an inability to maintain lipid stores, as seen through 
increased basal lipolysis, resulting in decreased fat mass (76, 77). Increased systemic 
lipid load has been suggested to be responsible for decreased insulin sensitivity in 




diminished HSL translocation, indicating that dyslipidemia may play an important role in 
adipocyte function.  
Monoacylglycerol Lipase 
The last lipase involved in lipolysis involves monoacylglycerol lipase (MGL). MGL 
hydrolyzes the final fatty acid from glycerol in a hormonally unregulated manner (78). 
MGL is required for lipolysis and the development of diet-induced insulin resistance 
(79). Due to the ability of MGL to deactivate endocannabinoid 2-arachidonoyl-sn-
glycerol (2-AG), a known player in central nervous system-mediated thermogenesis, 
overexpression of MGL resulted in increased energy expenditure (80). Together, ATGL, 
HSL, MGL, and their associated proteins combine to break down triglycerides to provide 
fatty acids to be used by other tissues as energy substrates, and the genetic ablation of 
these proteins result in defects in energy expenditure. 
Routes of Fatty Acid Efflux 
Fatty acids that accumulate intracellularly as a result of lipolysis are exported 
both by diffusion and facilitated transport, using transport proteins, across the adipocyte 
cell membrane on their way to the bloodstream for use by other tissues (81). Fatty acid 
translocase (FAT) (82), fatty acid binding protein plasma membrane (FABPpm) (83), 
fatty acid transport protein (FATP) (84), and caveolin-1 (85) all aid in fatty acid transport 
across the adipocyte cell membrane. In addition to binding perilipin, HSL interacts with 
fatty acid binding protein 4 (FABP4) (86-88) to facilitate the release of fatty acids out of 
adipocytes. Active transport has also been proposed for adipocyte fatty acid efflux, but 




Glycerol efflux occurs by facilitated transport primarily using aquaporin 7 in 
adipocytes (90). Aquaporin 7 knockout mice are obese and also have defects in 
catecholamine-induced glycerol release (90-92). This transporter is reduced in adipose 
tissue of obese subjects (93). FABP4 knockout mice have decreased basal and 
isoproterenol-stimulated lipolysis (88). In sum, not only is the ability to generate free 
fatty acids associated with obesity, but free fatty acid and glycerol transport out of the 
adipocyte are also important determinants of obesity. 
Adipose Tissue Blood Flow 
Fatty acid flux in and out of adipocytes involves coordination with vascular 
capillary beds. The importance of adipose tissue blood flow for regulating lipolysis has 
long been appreciated in human subjects. Blood flow increases through adipose tissue 
during times of lipid storage postprandially (94), as well as during times of lipid 
mobilization when fatty acids are released for use by other tissues (95, 96). These 
processes are regulated in part by adrenergic action in smooth muscle vascular cells.  
The inability to increase adipose tissue blood flow in obese subjects following 
exercise further suggests a role for adrenergic desensitization in obese adipose tissue 
(97, 98). In adipose tissue, response to epinephrine as lipolysis or adipose tissue blood 
flow were attenuated in obese subjects compared to lean ones (99). Lower fasting 
adipose tissue blood flow was observed in obese patients (94, 95).  
Regional Differences in Lipolysis 
Conflicting reports have emerged about regional differences in adipose tissue 
lipolysis. The consensus is that not all fat depots respond to adrenergic stimuli the 




visceral adipocytes, but visceral adipocytes respond more strongly, as measured in fold 
change, to adrenergic stimuli (100). Visceral fat depots respond more strongly to 
catecholamines compared to subcutaneous depots, which has been attributed to 
differences in β-adrenergic receptor levels (101), lipase levels (102), as well as levels of 
FABP4 (103). Finally, adipose depots also respond differentially to insulin; visceral 
adipose tissue does not respond as strongly to insulin as does subcutaneous tissue, 
which has been attributed to differences in insulin receptor levels (104), phosphorylation 
of insulin receptor and insulin receptor substrate-1 (IRS-1) (105), and tyrosine 
phosphatase activity on the insulin receptor (106). 
Attenuation of Lipolysis by Insulin 
Several molecules are known to negatively regulate lipolysis. Prostaglandins 
(107), nicotinic acid (108), adenosine (109), neuropeptide Y and peptide YY (110, 111), 
activate Gi and thereby inhibit adenylyl cyclase activity. Also, isoproterenol causes 
adipocytes to secrete adrenomedulin which generates autocrine negative feedback 
through a nitric oxide-dependent mechanism (112). However, insulin is the most well-
known suppressor of lipolysis. 
Insulin is the most powerful anabolic hormone (113). Insulin stimulates adipocyte 
differentiation and adipose tissue expansion. Insulin’s effects on adipose tissue 
expansion are attributed to its ability to inhibit lipolysis, stimulate the uptake of free fatty 
acids and glucose, and initiate de novo fatty acid synthesis. While skeletal muscle is the 
main tissue for insulin-stimulated glucose uptake, genetic ablation in adipose tissue of 
insulin-stimulated glucose transporter, GLUT4, produces defects in glucose 




defective glucose homeostasis in muscle-specific GLUT4 knockout mice (115). While 
the fat-specific insulin receptor knockout mouse has normal whole body glucose 
metabolism, these mice have reduced adipose tissue mass and extended lifespan 
(116).  
Insulin decreases lipolysis through a variety of targets. Insulin attenuates β-
adrenergic pathways by sequestering β-adrenergic receptors intracellularly (117), 
decreasing adenylyl cyclase activity (118), preventing localization of PKA to β-
adrenergic receptors (119), activating protein phosphatases to dephosphorylate HSL 
(120), and activating the phosphodiesterase 3B (PDE3B) (121). Whereas the activation 
of adenylyl cyclase produces cAMP, phosphodiesterases are responsible for cleaving 
cAMP to AMP to terminate PKA-dependent signaling. Therefore, the activation of 
phosphodiesterases by hormonal cues, such as insulin, promotes anabolic processes 
and decreases catabolic processes in adipose tissue. 
Phosphodiesterase 3B 
Phosphodiesterases comprise an eleven member superfamily in mammals 
(PDE1-11) with different catalytic specificities to cleave cAMP and cGMP that act in  
different cellular contexts (122). Although other phosphodiesterases have recently been 
implicated in adipocyte biology (123), PDE3B and PDE4 are the main 
phosphodiesterases that regulate cAMP in adipocytes (124). The PDE3 family is 
composed of two members with similar structural organization, PDE3A and PDE3B 
(125). PDE3A and PDE3B are encoded by separate genes and perform distinct 




However, PDE3A acts in cardiomyocytes and platelets, while PDE3B acts in white 
blood cells and in metabolic tissues, such as adipose tissue and liver.  
The PDE3B protein contains an N-terminal membrane-targeting domain that 
allows PDE3B to be retained on membranes, followed by a regulatory domain that is 
phosphorylated to alter function (125). Near the carboxy terminus is the catalytic domain 
and a distal, hydrophillic region. The catalytic domain of PDE3B has a Km value that has 
been measured to be between 100nM to 800nM for cAMP and has a 4-10 fold higher 
affinity and velocity for cAMP than cGMP.  
PDE3B is regulated by binding proteins, intracellular localization, and 
phosphorylation. PDE3B localizes to the plasma membrane, including lipid rafts and 
caveolae, and the endoplasmic reticulum through its N-terminal membrane-targeting 
domain (121, 126, 127). Caveolae are involutions of plasma membrane constructed of 
cholesterol and lipids stabilized by caveolin (128). These structures are concentrated in 
adipocytes to organize intracellular signaling events. Since PDE3B localizes to caveolin, 
PDE3B may be regulated by signaling processes occurring in this compartment.  
Interestingly, PDE3B is phosphorylated and activated in adipocytes and 
hepatocytes in response to both insulin and elevated cAMP levels. This is somewhat 
surprising; insulin and intracellular cAMP have antagonistic effects to each other. Insulin 
stimulates the phosphorylation and activation of PDE3B, which reduces cAMP to 
prevent lipolysis (129) (130). Insulin-stimulated reduction in cAMP also prevents 
activation of AMPK resulting in retention of fatty acids and decreased fatty acid 




activates PDE3B to act as negative feedback for cAMP-dependent signals (121). This is 
not exclusive to PDE3B function, as PDE4D3 can also be phosphorylated and activated 
by PKA to negatively regulate cAMP levels (132)  
Several serine residues in the regulatory domain of PDE3B are phosphorylated 
in response to insulin or cAMP in hepatocytes and adipocytes (125, 133-135). No 
phosphorylation site on PDE3B has been better characterized than serine 318 (human), 
which is a presumed consensus site for both Akt and PKA phosphorylation as well as a 
consensus 14-3-3 binding motif (133). In fact, PDE3B is thought to be activated by 
phosphorylation at human serine 318 in response to both insulin and cAMP (136), and 
14-3-3β binding protects this site from phosphatase-catalyzed dephosphorylation and 
inactivation (137). Several other phosphorylation sites that respond to insulin and 
forskolin have been identified, but they are less well characterized (133). 
Phosphorylation of PDE3B also depends on intracellular location and associated 
protein complexes, providing additional layers of complexity to PDE3B regulation. 
Insulin phosphorylates and activates PDE3B that is localized to the endoplasmic 
reticulum (135), while PKA-dependent phosphorylation of PDE3B occurs at the plasma 
membrane (135).  Insulin-stimulated PDE3B has been reported to form complexes with 
IRS1 and other insulin signaling intermediates, whereas PKA dependent PDE3B 
complexes contain the β-adrenergic receptor and hormone sensitive lipase (134, 135). 
Therefore, the co-localization of these two groups of molecules may be necessary for 





PDE3B serves important functions in obesity as well. While some studies 
suggest a reduction of PDE3B in obesity, much of our understanding of the role of 
PDE3B in vivo for obesity is gleaned from the Pde3B knockout mice (138). Importantly, 
PDE3B was essential for reduced white adipose tissue and increased lean mass, which 
were attributed to increases in lipolysis in Pde3B knockout mice. Knockout mice 
revealed a role for PDE3B in expanding adipose tissue depots and promoting weight 
gain while on a high-fat diet, (121). Livers from these mice failed to reduce glucose 
output in response to insulin, which was correlated with upregulated gluconeogenic 
genes (138, 139). Several studies reported decreased PDE3B activity in adipose tissue 
of obese subjects (140-143), which may contribute to insulin resistance. These studies 
demonstrate the role of PDE3B in anabolism and its potential contribution to 














Activation of UCP1 
Adaptive thermogenesis is due in part to the activation of UCP1 by free fatty 
acids from lipolysis (13). Thermogenic responses in brown-fat cells are fully UCP1-
dependent for adrenergic or fatty-acid induced thermogenesis (144). This suggests that 
the induction of thermogenesis from lipolysis is inextricable; thermogenesis does not 
occur without hormonally-induced lipolysis-dependent free fatty acids. This process is 
dependent on PKA, since UCP1 gene expression and thermogenesis is inhibited by the 
PKA inhibitor H89 (145).  The current model that exists for UCP1 activation is that fatty 
acids serve as thermogenic substrates for UCP1, and GDP effectively competes with 
free fatty acids to prevent UCP1 action (13). The proton gradient that UCP1 dissipates 
to achieve thermogenesis is derived from fatty acids undergoing β-oxidation or 
carbohydrates undergoing glycolysis. Metabolized energy substrates therefore provide 
the proton gradient, through glycolytic and TCA cycles, and free fatty acids directly 
activate UCP1 activity. UCP1 in adipose tissue is not only controlled by free fatty acids, 
but UCP1 is also regulated on a transcriptional level, which is also partly due to β-
adrenergic signaling (13). Therefore, transcriptional control of thermogenic programs in 
adipocytes warrant further discussion. 
Adipocyte Development and Differentiation 
To understand the thermogenic potential of adipocytes, we must first understand 
how brown and white adipocytes develop. Fat is of mesenchymal origin. It is currently 
thought that brown and white adipocytes diverge early in mesenchymal stem cell 




White Adipocyte Development and Differentiation 
Adipogenesis has been studied extensively in 3T3-L1 adipocytes (147). Some of 
the first transcription factors known to initiate adipogenesis were the CCAAT/enhancer 
binding proteins (c/EBPs) (148, 149). c/EBPβ and δ mRNA and protein levels increase 
early in the differentiation process, but taper off later in the adipogenic program. c/EBPα 
is induced later in the differentiation process, and precedes maximal insulin-stimulated 
glucose uptake in adipocytes. Early experiments with c/EBPα showed that ectopic 
expression of c/EBPα promotes adipogenic program (150), and c/EBPα loss-of-function 
blocks adipogenesis (151).  
PPARγ is the master regulator of adipogenesis (147). Early experiments in 
adipocyte differentiation demonstrated that PPARγ expression is sufficient to induce the 
adipogenic program (152). Also, c/EBPα was able to cooperate with PPARγ to stimulate 
the adipocyte program dramatically. Together, PPARγ and c/EBPα drive adipogenesis. 
Factors that increase cAMP strongly accelerate the initiation of the adipogenic 
differentiation program by suppressing Wnt10b  and promoting c/EBPβ (153).  cAMP 
stimulates CREB early in adipocyte differentiation to result in c/EBPβ expression (154). 
Wnt signaling inhibits adipocyte differentiation in 3T3-L1 cells by suppressing PPARγ 
and c/EBPα expression (147). cAMP results in methylation of the Wnt10b, preventing 
Wnt10b expression and promoting adipogenesis (155). Therefore, the ability of cAMP to 
promote c/EBPβ expression and downregulate Wnt10b are partly responsible for the 




Brown Adipocyte Development and Differentiation 
Brown fat is surprisingly more closely related developmentally to muscle than it is 
to white fat (156). Brown adipocytes and muscle both descend from dermomyotome 
precursors that express Engrailed-1 (157). Interscapular BAT is present in rodents and 
newborns, but this depot disappears postnatally in humans. White adipose tissue 
develops later and continues to expand after birth (158).  In mice, cells that express 
myf5, a marker of skeletal muscle precursors, were found in brown, but not white, 
adipose depots (156). Expression of PR domain containing-16 (PRDM16) in skeletal 
myoblasts promoted differentiation toward a brown adipocyte fate (156, 159). PRDM16 
was found in complex with PPARγ and c/EBPβ (156, 159). PRDM16 can bind to either 
the PPARγ-PPARα transcriptional complex or c/EBPβ to coactivate their transcriptional 
effects and drive brown adipogenic differentiation. 
Functions of Brown and White Adipose Tissue 
The main function of brown adipose tissue is to transfer energy into heat using its 
extraordinarily high concentration of mitochondria and UCP1 (13).  While white adipose 
tissue has been established as a dynamic tissue involved in neurohormonal control, one 
of its main functions is as an energy reservoir to flexibly release or store fatty acids 
depending on the energy needs of an animal, including during adaptive thermogenesis 
(160). In this sense, brown and white adipocytes have functionally opposite, but 
complementary, roles in energy consumption and storage.  
Brown Adipocytes in White Adipose Depots 
It has been reported in mice that brown adipocytes can emerge in white adipose 




162).  Brown adipocyte recruitment into white depots is thought to have evolved to 
protect the body from hypothermia, serving as an extension of the normal role of brown 
adipocytes in BAT. The upregulation of UCP1 through brown adipocyte recruitment to 
white adipose depots is mediated by many of the same players that control UCP1 
expression in BAT (13). Just like in BAT, adaptive thermogenic sympathetic outflow 
from cold exposure and dietary sources results in neural stimulation of WAT (163). In 
fact, there are common neurons in sympathetic nervous system outflow circuits to WAT 
and BAT that are traced back to the hypothalamus (164). 
Brown adipocytes emerge in white adipose tissue in response to cold exposure 
or a β3-specific adrenergic agonist, CL-316243 (165). These cells were initially 
proposed to result from a transdifferentiation of white adipocytes to brown adipocytes 
(166), but whether brown adipocytes in white adipose depots are due to 
transdifferentiation or differentiation of brown-like preadipocyte precursors in white 
adipose tissue remains unclear (162).  
Recruited brown adipocytes from mice treated with the β-3 adrenergic agonist 
CL-316243 are derived from a non-myf5 expressing lineage, suggesting a separate 
progenitor cell from brown adipose depots and skeletal myocytes (156). Chronic PPARγ 
activation of epididymally-derived white adipocyte cultures revealed a population of 
thermogenically competent, UCP1-containing adipocytes which are distinct from classic 
brown adipocytes (167). These cells were named “beige” adipocytes for their shared 
brown and white adipocyte characteristics. Other groups have also isolated beige 
preadipocytes from white adipose tissue (162). Unlike white adipocytes, differentiated 




also do not descend from a myf-5 lineage. Interestingly, the brown fat in adult humans 
has more beige molecular characteristics that brown adipose cells. In agreement with 
lineage studies, the loci responsible for controlling cold-induced brown adipocytes in 
white adipose depots vary from those that control interscapular brown fat (168). These 
studies suggest an adipocyte precursor, not of brown lineage, differentiate into an 
adipocyte that responds more strongly to adrenergic stimulation and PPARγ agonists 
than white adipocytes to develop thermogenic capacity. Regardless of what color we 
assign it, when white adipose tissue serves as an adaptive thermogenic organ, it will 
likely be through the induction of UCP1 transcription and its sympathetic stimulation in 
adipocytes. 
Transcriptional Control of UCP1  
The thermogenic function of brown adipose tissue can be traced back to its 
utilization of UCP1. Any adipocyte that has significant amounts of UCP1 can contribute 
to thermogenesis and increase energy expenditure. Therefore, to understand the 
thermogenic role of brown adipocytes in any adipose depot, it is important to 
understand the transcriptional control of UCP1. 
PKA 
Integration of thermogenic cues in the hypothalamus results in stimulation of the 
sympathetic chain, thereby releasing norepinephrine locally in brown adipose tissue 
(13). Activation of G-protein coupled β-adrenergic receptors on brown adipocytes allows 
Gs to activate adenylyl cyclase to produce cAMP that activates PKA. PKA activity alone 
is sufficient to induce UCP1 and other thermogenic gene expression, resulting in 




expression and thermogenesis by H89 indicates protein kinase A mediation of β3-
adrenergic signaling is required for adipocyte thermogenic function (145). Therefore, 
PKA is a central mediator of UCP1 transcription and thermogenesis. 
PKA expression is regulated by the FoxC2 transcription factor. FoxC2 induces 
the expression of PKA regulatory subunit to enhance β-adrenergic and thermogenic 
signaling, and FoxC2 also enhances angiogenesis (170). Transgenic expression of 
FoxC2 in adipocytes showed this transcription factor is sufficient to downregulate 
obesity and metabolic disease (171). pRb suppresses FoxC2 expression, and functional 
inactivation of pRb results in increased PKA subunit RIα and UCP1 transcription (172). 
PKA Targets: CREB and p38 
One of the first traditional PKA targets established to affect UCP1 transcription 
was cAMP response element binding protein (CREB) (173). PKA phosphorylates and 
activates CREB, which functions as a transcription factor in a variety of processes 
(174). cAMP response elements are found in a 220 base pair region of the UCP1 
promoter that were essential for induction of UCP1 by norepinephrine (173).  
The MAPK pathway plays a role in UCP1 transcription (175). In adipocytes, 
upregulation of UCP1 transcription by β-adrenergic stimulation is controlled by p38 via 
PKA (175). PKA activates p38α through MAP kinase kinase 3 and is responsible for the 
induction of UCP1 in response to β-adrenergic stimuli (176). p38 controls UCP1 
transcription by phosphorylating both activating transcription factor 2 and PGC-1α (177). 




obesity resistant A/J strain compared to C57BL/6 (178). Together, these studies 
suggest an important role of p38 in UCP1 upregulation. 
c/EBPs 
PPARγ and members of the CCAAT/enhancer-binding protein (c/EBP) family of 
transcription factors are important transcriptional regulators of both white and brown 
adipocyte differentiation (147, 153). However the expression of c/EBPβ is higher in 
brown adipocytes versus white adipocytes. When c/EBPβ is absent, thermoregulation 
and lipid metabolism is compromised (179). When c/EBPβ is enriched in white 
adipocytes, they acquire more of a brown adipocyte pattern of gene expression (180). 
Additionally, c/EBPβ promotes conversion of myoblasts to brown adipocytes (159). 
Binding sites for c/EBPα and c/EBPβ are present in the proximal UCP1 promoter (181).  
The c/EBPβ knockout mice have defective thermoregulation and impaired lipid 
metabolism (179). One study of white, northern European families found 11 allelic 
variants in c/EBPα and 12 variants of c/EBPβ that could potentially influence abdominal 
obesity and related metabolic abnormalities associated with type 2 diabetes and 
cardiovascular disease, such as leptin and adiponectin levels (182). In sum, regulation 
of UCP1 transcription by the c/EBP family of proteins is important for thermogenesis. 
Thyroid Hormone 
UCP1 transcription in BAT is also regulated by thyroid hormone, which is 
converted to its active form by deiodinase d2, the thyroid hormone converting enzyme, 
locally in adipose tissue (183). Thyroid hormone action in adipocytes increases UCP1 
gene expression via thyroid hormone nuclear receptors, which enhance the 




acts synergistically with norepinephrine to induce expression of UCP1 in adipocytes 
(185). Two thyroid responsive elements are found 27 bp apart between −2·33 kb and 
−2·39 kb in the UCP1 promoter (186). The synergism between cAMP and thyroid 
hormone seems to reside in a 39 bp sequence downstream (−2·28/−2·32 kb). Thyroid 
hormone, therefore, potentiates UCP1 expression to facilitate adaptive thermogenesis 
in adipose tissue. 
Peroxisome proliferator-activated receptors (PPARs) 
 In brown adipocyte development, PPARs have important functions. Studies have 
demonstrated that PPARγ agonists cause white adipose depots to take on brown 
adipocyte characteristics (167). These adipocytes are smaller, have greater insulin 
sensitivity, and animals show overall improvements in metabolic health (187). White 
adipocytes have increased mitochondrial remodeling and biogenesis (188, 189), as well 
as blunting of proinflammatory cytokine production and inflammatory transcriptional 
profiles in response to PPARγ agonists (190, 191). PPARγ agonists are also able to 
increase transcription of UCP1 (192), PGC-1α (193) and Cidea (194) in white 
adipocytes. 
PPARα has also been strongly linked to UCP1 transcription (178) as well as 
pathways involved in lipid oxidation and energy expenditure in brown adipocytes (195), 
suggesting PPARα is important for adaptive thermogenesis. PPARα and PPARγ bind 
the UCP1 promoter in the −2485/−2458 base pair region to stimulate UCP1 expression 
(195). Surprisingly, PPARα-knockout mice do not have impaired BAT function, and it is 





PPARγ coactivator-1α (PGC-1α) is a coactivator of many transcription factors, 
including PPARs, driving UCP1 transcription. Overexpression of PGC-1α in white 
adipocytes results in brown thermogenic expression, including UCP1 and deiodinase d2 
(161, 196). Sympathetic stimulation fails to induce UCP1 in brown adipocytes isolated 
from PGC-1α knockout mice (197). PGC-1β can compensate for the loss of PGC-1α in 
brown adipocyte differentiation and mitochondrial biogenesis. PGC-1α knockout mice 
have a variety of metabolic derangements (198), they are unable to defend core body 
temperature during cold exposure due to defective adaptive thermogenesis (199). In 
humans, polymorphisms in the PGC-1α gene, especially Gly482Ser, have been 
associated with diabetes and its complications (200). 
Repressors of PGC-1α 
In addition to transcriptional activators of brown adipocyte features, genetic 
deletion mouse models reveal contributions of multiple factors to downregulate the 
brown phenotypic program. Several of these factors are proposed to act through PGC-
1α. pRb binds and represses the PGC-1α promoter (201). RIP140 binds PGC-1α to 
inhibit its coactivation of thermogenic transcription factors (201, 202). RIP140 knockout 
mice have decreased fat accumulation (203) along with increased oxidative metabolism 
and mitochondrial biogenesis (204). Similarly, twist-1, another transcriptional repressor, 
binds PGC-1α to provide negative feedback on PPAR complex activity (205). The 
nuclear receptor LXRα behaves as a transcriptional repressor by inhibiting the PGC-1α, 
PPARγ complex from binding the UCP1 promoter (206). Whether brown and white 





One protein that drives brown adipocyte cell fate is the PR domain containing-16 
(PRDM16) zinc finger transcription factor (207). Expression of PRDM16 in fibroblasts or 
white preadipocytes promotes brown adipocyte differentiation. Transgenic expression of 
PRDM16 in white adipocytes results in resistance to obesity and the emergence of 
brown adipocytes in white adipose depots. PRDM16 knockout mice die shortly after 
birth and show large lipid droplets and impaired thermogenic gene expression, including 
UCP1 and PGC-1α, in brown adipose depots combined with increased skeletal muscle 
transcriptional profile. Reduction of PRDM16 transcripts in isolated brown preadipocytes 
also attenuates brown adipocyte thermogenic gene expression in favor of a skeletal 
myocyte phenotype (156).  
The expression of UCP1 is inextricable from brown adipocyte thermogenic 
potential. As we have discussed, many factors contribute to brown adipocyte UCP1 















Thermogenesis and UCP1 
Since brown adipocytes have been identified in humans, there is added potential 
for UCP1 to alleviate obesity and metabolic disease (208-213). Transgenic adipose-
specific UCP1 expression is cytotoxic to brown adipose tissue, yet still protects animals 
from diet-induced obesity by enhancing fatty acid oxidation and decreasing lipogenesis 
in WAT (214). In the following section, I will review the role of UCP1 on whole animal 
physiology. A more extensive review by Cannon was done in 2004 (13), but this field 
has expanded significantly since then.  
As an overview, the UCP1 knockout mouse has allowed us to study the 
physiological significance of UCP1 in the proton uncoupling functions of adipose tissue 
(215). Reduction in adipose tissue mass from either β-adrenergic agonists or leptin can 
be largely attributed to UCP1 dependent processes. When brown adipose activity is 
reduced, animals readily gain weight. The ability of brown adipose tissue to absorb and 
utilize glucose also is dependent on thermogenesis. However, other thermogenic 
processes are not dependent on UCP1 activity. The properties of brown adipose tissue, 
and its recent identification in humans, allows for the possibility that brown adipocytes 
may play a significant role in energy balance in humans. The consistent theme from this 
field is that both UCP1 and adrenergic activation are required for a robust nonshivering 
thermogenic response. 
Adaptive Thermogenesis in Adipose Tissue 
Cold exposure and adaptation to diet are linked to adaptive adrenergic 
thermogenesis (215). Both of these processes depend on the presence of UCP1. There 




both wild type and UCP1 knockout mice (216), suggesting that this effect is UCP1 
independent. However, a 10% change in thermogenesis is not a sufficient response to 
protect against hypothermia (which requires ~400% increase), so UCP1-independent 
thermogenesis is not considered to be sufficient for survival in colder temperatures.  
UCP1-independent Thermogenic Processes. 
Fever is a thermogenic response that is mostly UCP1-independent. The febrile 
response is recruited as a specific response to pathogens. UCP1 is not necessary for 
febrile response, although it can be stimulated in a febrile response (215). The body 
uses all means necessary, but a loss of nonshivering thermogenesis does not prevent 
fever. Adipokines, such as interleukin-6 , may be released from adipose tissue into 
circulation to further the febrile response (215). However, the role of brown adipose 
tissue in fever is limited. 
Thermogenic responses to adrenergic stimuli exist outside of brown adipose 
tissue UCP1 (216-218). The heart increases its metabolism by increasing rhythmicity 
and contractility of cardiac muscle in response to sympathetic activation, which requires 
ATP through coupled aerobic respiration (215). This results in increased biochemical 
reactions that, consequently, give off more heat. Sustained sympathetic stimulation on 
tissues other than BAT, such as cardiac and skeletal muscle, however, will not 
adaptively increase thermogenesis over time. In contrast, brown adipose tissue that is 
recruited for adaptive purposes by sympathetic stimulation will yield a much larger 





UCP1-independent Cold-induced Thermogenesis 
Animals presented with a cold challenge protect body temperature through 
shivering and nonshivering thermogenesis, and both contribute to maintaining body 
temperature (215). A mouse acutely exposed to cold depends primarily on shivering 
thermogenesis to meet its needs until brown adipose tissue is recruited (219, 220). Cold 
exposure also leads to changes in the acyl-phospholipid composition in the 
mitochondrial membrane of brown adipocytes (221). Membrane composition is an 
important determinant of native proton conductance and thermogenesis in mammals 
compared to other species, and differences in lipid composition of mitochondrial 
membranes are independent of UCP1 activity. Angiogenesis in brown adipose tissue 
requires adrenergic stimulation from cold exposure to aid in thermogenesis (222). 
Adrenergic stimulation results in the release of VEGF in brown adipose tissue, but does 
not depend on UCP1 as well(222, 223). 
UCP1-dependent Thermogenesis 
The role of UCP1 in brown adipose thermogenesis has become more accessible 
with the creation of UCP1 knockout mice (224). UCP1 from brown adipocytes has been 
reported to be completely necessary for β-adrenergic stimulated non-shivering 
thermogenesis (144, 225). 
Norepinephrine-induced Thermogenesis 
At the time that the nonshivering thermogenesis field was in its infancy, it was 
observed that recruitment of nonshivering thermogenesis was paired with a potentiation 
of thermogenesis in response to injected catecholamines (215). Many years later, it was 




catecholamines (215). Norepinephrine is responsible for cold-induced adaptive 
thermogenesis by stimulating both β3 and α1 adrenergic receptors in rodents (226-230). 
Therefore, norepinephrine from the sympathetic chain is essential to nonshivering 
thermogenesis. 
UCP1-dependent Nonshivering Thermogenesis 
Non-shivering thermogenesis is a specialized heat producing mechanism in 
mammals that is elicited by cold exposure. Initially, shivering dramatically increases 
heat production (219, 220). Gradually, shivering heat production is replaced by 
nonshivering adaptive thermogenesis (215). Although first thought to occur in muscle, 
the characterization of the UCP1 knockout mouse demonstrated that brown adipose 
tissue is responsible for nonshivering thermogenesis, as these mice continue to shiver 
with prolonged cold exposure (219). Furthermore, no other uncoupling protein or 
metabolic process can substitute for UCP1 in brown adipose tissue to mediate 
nonshivering thermogenesis (231). Whereas cold exposure does not normally decrease 
lifespan (232), UCP1 knockout mice exposed to cold have significantly decreased 
lifespan (219). Together, these studies suggest a primary role for UCP1 in nonshivering 
thermogenesis and survival in cold environments. 
Diet-induced Thermogenesis 
Diet-induced thermogenesis is a difficult-to-define phenomenon that, for the 
purposes of clarity, will exclude the energy expended in the digestion of nutritional 
macromolecules. High-fat diet increases norepinephrine-induced thermogenesis, which 
is dependent on the presence of UCP1 in mice (217). However, the idea that diet-




within the field (233). Leptin is released from expanded adipose tissue to act on the 
hypothalamus to decrease food intake and increase energy expenditure through 
thermogenesis (234). Early studies showed that leptin-deficient animals have a 
thermogenic defect (235). Interestingly, UCP1 is required for leptin-stimulated increases 
in energy expenditure and reductions in white adipose tissue in pair fed mice (236). 
Therefore, humans would need substantial brown adipose tissue to increase 
thermogenesis to respond to leptin infusion. It has also reported that brown adipose 
tissue can respond to a single meal, which may or may not be independent of leptin-
induced dietary thermogenesis (237). However, for all intents and purposes, both cold-










UCP1 is Required to Prevent Obesity 
Obesity occurs when animals experience a chronic positive energy balance. This 
is accomplished through either an increase in calorie intake or a decrease in energy 
expenditure. As mentioned before, “with few exceptions, most rodent models of obesity 
have defects in adaptive thermogenesis” (12). Researchers have tried for a long time to 
find a thermogenic defect in obesity, but results have been mixed (233). One possibility 
is that the thermogenic activity is maintained in obesity, but increases in thermogenic 
potential are held in check by negative regulators of adaptive thermogenesis. So far, 
only one polymorphism related to UCP1 expression has been described (238), and the 
correlation between that polymorphism and obesity has generated mixed results (239, 
240). This suggests that defects related to UCP1 are not due to UCP1 variant inaction. 
Instead, primary defects in obesity and metabolism may be related to the 
pathophysiologic control of UCP1 activity, such as defects in lipolysis and UCP1 
transcription. Regardless of source, the presence of UCP1 in animals has a profound 
effect on metabolism. Since UCP1 is responsible for adaptive thermogenesis, the UCP1 
knockout mouse provides an important model for defective adaptive thermogenesis in 
obesity. 
UCP1-ablated Mice Become Fat in a Thermoneutral Environment 
Thermoneutrality, or the temperature at which an organism expends the least 
amount of energy to maintain homeothermy, varies from animal to animal. Humans 
prefer a lower ambient temperature than mice because clothes and other environmental 
modifiers can protect homeothermy. Mouse thermoneutrality is approximately 30°C, and 




temperatures beneath thermoneutrality paradoxically showed resistance to obesity 
(224, 242), and no obesogenic effect was observed in UCP1 knockout mice raised just 
beneath thermoneutrality (242, 243). However, UCP1 is required to maintain lower body 
weights even on a normal diet under thermoneutral conditions (217), and this phenotype 
is exacerbated by high-fat feeding. Along with increased susceptibility to obesity with 
high-fat diet, the obesogenic effect is more prominent with age in UCP1 knockout mice 
(244). These experiments highlight how important the thermal environment is to altering 
UCP1-dependent phenotypes.  
Effects of β3 agonists on Weight 
β3 agonists reportedly increase aerobic energy expenditure in mice, even in the 
absence of UCP1 (218, 245); however, several groups have not seen a UCP1-
independent thermogenic response to β3 agonists (215, 243), making UCP1-
independent β3 thermogenic responses in mice controversial. Perhaps, increased 
metabolism observed in mice treated with β3 agonists may be attributed to tissues other 
than brown adipose tissue because of the known involvement of the β3 receptor in the 
metabolism of a variety of tissues, including heart, gall bladder, gastrointestinal tract, 
prostate, urinary bladder detrusor, brain and near-term myometrium (246). Regardless, 
weight loss in response to β3 agonists occurs in the presence of UCP1 (218), 
suggesting an essential role for brown adipose tissue in this process. Therefore, the 
weight reducing potential of β3 agonists may only be effective in animals with substantial 
amounts of brown fat already. Brown adipocyte proliferation is a β1 receptor stimulated 
process (247) and not a β3 stimulated process (248, 249). Because brown 




brown adipocyte proliferation before the beneficial effects of β3 agonists are possible in 
animals lacking significant numbers of adipocytes with brown features, including 
humans. Additionally, the thermogenic potential of beige precursor cells in white 
adipose tissue may require a more thorough understanding of how these cells 
proliferate (162). Since the presence of sufficient thermogenic cells and adrenergic 
receptors in human adipose tissue is also controversial, the potential of brown adipose 
activity in human obesity remains ambiguous (208, 251, 252). 
UCP1-dependent Catecholamine-stimulated Glucose Uptake 
Although the dogma surrounding the UCP1 field is that lipid is the only important 
energy substrate for adaptive thermogenesis, respiratory quotient experiments during 
cold exposure indicate that both glucose and lipid are utilized concurrently, allowing for 
the possibility that UCP1-laden cells could reduce blood glucose in the context of 
obesity and type 2 diabetes (215). Uptake of glucose into brown adipose tissue has 
been observed in rodents exposed to cold (253), and glucose uptake is the how brown 
adipose tissue was first identified in human patients (208). Additionally, glucose uptake 
is induced by norepinephrine in wild type mice, but is absent in UCP1 knockout mice 
(254). Stimulation of isolated brown adipocyte with norepinephrine also results in 
increased glucose uptake, which further implicates a role for brown adipose tissue 
glucose uptake in thermogenesis.  
Since extra heat during chronic cold exposure comes exclusively from brown 
adipose tissue, it reasons that brown adipose tissue is either mobilizing stored 
carbohydrates or absorbing glucose from the blood stream for consumption. Therefore, 




will eventually be used to generate a proton gradient to be dissipated by UCP1 in 
mitochondria. Therefore, humans with less brown adipose tissue do not have this 
additional mechanism to uptake glucose from the bloodstream and utilize that glucose 
for thermogenesis, perhaps making these individuals more susceptible to metabolic 
dysfunction that leads to high blood glucose. 
Inflammation in Obesity 
Metabolic and immune functions are essential to life, and these systems are 
highly conserved and integrated. Consequently, dysfunction in either system results in a 
variety of maladies with both metabolic and immunologic features, including obesity (1). 
Obesity produces a state of chronic, low-grade inflammation in liver and fat 
accompanied by macrophage infiltration and the local secretion of inflammatory 
cytokines and chemokines (1, 255, 256). The resulting increase in TNFα and other 
cytokines creates a sustained cycle of adipocyte lipolysis and inflammatory crosstalk 
between adipocytes and recruited macrophages, activating the inhibitor of kappaB 
kinase β (IKKβ)-nuclear factor κB (NFκB) pathway in both tissue types (255). 
Multiple metabolic stressors are thought to work through IKKβ and NFκB. 
Circulating free fatty acids, interleukin 1, TNFα, advanced glycated end products, 
glucosamine, and ER stress have all been linked to NFκB in insulin resistance (257). 
Increased NFκB has also been observed in the hypothalamus of mice fed a high-fat 
diet. Mice with neural-specific knockout of IKKβ are resistant to diet-induced obesity, 
which is attributed to decreased food intake (258). Therefore IKKβ-NFκB has been 
implicated in each stage of the pathogenesis of insulin resistance. However, IKKβ and 




NFκB in Immunology 
The NFκB family of transcription factors regulates inflammation, along with a 
variety of stress-oriented cellular responses (259). NFκB activity is an important effector 
of inflammatory cell surface receptors, such as Toll-like receptors (TLRs) (260), and 
receptors of proinflammatory cytokines, including TNFα (261). TLRs recognize 
pathogen-associated molecular patterns, such as lipopolysaccharide (LPS) and double 
stranded RNA (dsRNA), which trigger inflammatory signals that orchestrate immune cell 
action to clear microbes from the body (260). Both TLRs and TNFα receptors (TNFRs) 
initiate inflammatory signaling cascades using protein adaptors and polyubiquitin ligases 
that colocalize with these receptors (259). TGFβ activated protein kinase (TAK1) is 
bound by TAK1-binding proteins (TABs), which are phosphorylated in response to 
inflammatory stimuli, and are necessary for TAK1 stability and activity (262-265). TAK1 
activity simultaneously leads to parallel MAPK (p38, JNK) and IKK pathway 
phosphorylation and activation (266). With respect to IKKs, TLR and TNFα stimulation 
leads to receptor interacting protein 1 (RIP1) polyubiquitination, which recruits the IKK 
complex regulatory scaffolding protein NEMO to TAB-TAK1, so that TAK1 
phosphorylates and activates the IKKβ (267) (268). 
Active IKKβ phosphorylates the inhibitor of κB (IκB), which results in IκB 
polyubiquitination and subsequent degradation through the 26S proteosome, and 
activation of NFκB (269). The NFκB family comprises five subunits that act as dimeric 
transcription factors (259). Family members have a conserved Rel homology domain 
that is responsible for dimerization, promoter binding, and forming a complex with the 




degradation of IκB exposes the nuclear translocation sequence of NFκB allowing this 
transcription factor to translocate to the nucleus and control the expression of 
inflammatory target genes.  
The IKK family of proteins: IKKα, IKKβ, TBK1, and IKKε  
The IKK family of proteins is composed of four members: IKKα, IKKβ, IKKε, and 
TANK-binding kinase (TBK1) (259). Similarities and differences exist in IKK family 
member function. Whereas IKKα and IKKβ complex with their regulatory subunit NEMO 
to make the canonical heterotrimeric IKK complex, IKKε and TBK1 complex with their 
regulatory subunit, TANK, to form the noncanonical IKK-related kinase complex (259). 
The canonical complex is proposed to exist as a large oligomer with additional adaptor 
proteins, and the complex is modified by phosphorylation. IKKβ is essential for 
mediating innate immune responses, including TLR and TNFα signaling, while IKKα is 
more important for regulating adaptive immunity and lymphoid organogenesis (270). 
IKKε and TBK1, also known as IKK-related kinases, were initially identified in the 
thymus, white blood cells, and lymphoid organs (271). IKKε and TBK1 phosphorylate 
interferon regulatory factors (IRFs), which then translocate to the nucleus to promote 
the expression of type I interferon genes, such as interferon β, to coordinate antiviral 
responses (272-274). The transcription of IKKε is induced by NFκB from canonical IKKβ 
activity (275). Therefore, IKKε is an inducible downstream mediator of NFκB 
inflammation. 
Recent studies have shown that there is cross-talk between canonical IKK and 
IKK-related kinase signaling pathways facilitated by the binding of NEMO and TANK 




pathway, which subsequently phosphorylate the activation loop Ser172 of IKK-related 
kinases. IKK-related kinases then negatively regulate the canonical IKK complex to 
dampen NFκB signaling as a feedback mechanism . 
Activation of IKKε is rapid, transient, and precedes prolonged TBK1 activation 
(277). TANK is required for IKKε and TBK1 activation, and the interaction between the 
IKK canonical complex and the IKK-related kinase complex depends on TANK and 
NEMO. However, phosphorylation of IRF3 and interferon β production do not require 
TANK. Therefore, IKKε and TBK1 can mediate the antiviral response through the 
formation of TANK-independent complexes (278). 
The IKK family regulates many facets of immune responses, but kinase activity of 
IKK family members occurs through a conserved pattern, as phosphorylation of 
activation loop serine residues is important for IKK family kinase activation. TAK1 
phosphorylates IKKβ on activation loop serine 177/181 between kinase subdomains VII 
and VIII causing a conformational change leading to IKKβ activation (279). Substitution 
of alanine for serine 177/181 dramatically reduces IKKβ activity, while substitution for 
phosphomimetic glutamate generates a constituitively active kinase (280, 281). 
Phosphorylation of serine 172 on TBK1 and IKKε has been associated with increased 
activity, and this residue is required for activity (282, 283). Therefore, phosphorylation of 
the activation loop is strongly indicative of IKK family member activity. 
Several phosphatases are important for the dephosphorylation of the activation 
loop to terminate IKK family member activity (284, 285). From the phosphoprotein 




phosphoprotein phosphatase M (PPM) family, which require Mn2+/Mg2+ metal ions, 
PPM1A and PPM1B decrease IKKβ activity (284). PPM1B negatively regulates antiviral 
responses by dephosphorylating serine 172 of TBK1 (285). TAB1 functions as a 
pseudophosphatase, and it has close structural similarity to PPM family phosphatases 
(286). In sum, the regulation of IKK family member activation loop phosphorylation by 
upstream kinases and phosphatases is highly regulated.  
Rationale for Project 
Since it is well-known that IKKβ affects insulin sensitivity (255), we set out to 
establish what effects other IKK family members have on energy balance in mice, 
especially IKKε and TBK1. When I entered the lab, our group was characterizing the 
IKKε knockout mouse (287) on a high fat diet. Using the IKKε knockout mouse, our lab 
discovered that IKKε is required for diet-induced weight gain, decreased energy 
expenditure, decreased insulin sensitivity, increased hepatic steatosis, and systemic 
inflammation (288). IKKε knockout mice had increased energy expenditure and UCP1 
levels in white adipose tissue on a high-fat diet. Furthermore, pharmacologic inhibition 
of IKKε and TBK1 recapitulated the knockout phenotype (Chiang and Reilly, 
unpublished). The main objective of my graduate years was to determine the 







Chapter II:  
IKKε and TBK1 Promote Obesity by Decreasing Energy 
Expenditure and UCP1 in Adipose Tissue 
Abstract 
 The IKK family of proteins has been linked to insulin resistance. In this chapter, 
we explore the effect on IKKε and TBK1 on metabolism, especially in adipose tissue. 
High fat diet increased IKKε and TBK1 protein levels in adipose tissue. Genetic ablation 
of IKKε or pharmacologic inhibition of IKKε and TBK1, using the selective inhibitor 
amlexanox, in mice resulted in many metabolic improvements, including reduced weight 
gain on a high-fat diet. These improvements were correlated with increased energy 
expenditure, core body temperature, adipocyte hyperplasia, and UCP1 protein levels in 
adipose tissue. Inhibitors of IKKε and TBK1 promote lipid accumulation and adipocyte 
proliferation in 3T3-L1 adipocyte differentiation. Treating 3T3-L1 adipocytes with 
amlexanox produced a dose-dependent increase in lipolysis and oxygen consumption. 
These studies suggested that IKKε and TBK1 diminish β-adrenergic/cAMP-dependent 
processes in adipocytes to regulate energy expenditure. 
Introduction 
The innate immune system has evolved to combat viral, bacterial, and other 




inflammation, which participates in the pathogenesis of a variety of diseases, including 
obesity, insulin resistance and type 2 diabetes (1). Obesity is accompanied by a state of 
low-grade, chronic inflammation in adipose tissue and liver that results in insulin 
resistance (255, 256). Overnutrition stimulates macrophage infiltration in adipose tissue.  
The resulting increase in TNF-α and other cytokines creates a sustained cycle of 
adipocyte lipolysis and inflammatory crosstalk between adipocytes and recruited 
macrophages (289), activating the IKKβ-NFκB pathway (255, 257). Multiple metabolic 
stressors are thought to work through IKKβ and NFκB. Circulating free fatty acids, 
interleukin 1, TNFα, advanced glycated end products, glucosamine, and ER stress have 
all been linked to  NFκB in insulin resistance (257). Increased NFκB has also been 
observed in the hypothalamus of mice fed a high fat diet. Mice with a neural-specific 
knockout of IKKβ are resistant to diet-induced obesity, which is attributed to decreased 
food intake (258). Therefore IKKβ-NFκB has been implicated in each stage of the 
pathogenesis of insulin resistance. 
The IKK family of proteins is composed of four members, IKKα, IKKβ, IKKε, and 
TBK1 (TANK Binding Kinase 1) (259). While IKKα and IKKβ stimulate the canonical 
NFκB pathway, the roles of IKKε and TBK1 are less well understood. IKKε was initially 
thought to phosphorylate the traditional IKK substrate IκB (290), but the list of IKKε 
substrates has expanded to include other NFκB proteins, interferon regulatory factors 
(IRFs), and STATs (291). The transcription of IKKε is controlled by NFκB from canonical 
IKKβ activity (275). Therefore, IKKε is an inducible mediator of NFκB inflammation. 
Given the role of IKKβ in generating insulin resistance, our lab set out to 




diet-induced obesity. Our lab discovered that a high fat diet induces NFκB activity and 
the expression of IKKε in white adipose tissue (WAT) of wild type mice (288). Much like 
IKKβ deficient mice (255), IKKε knockout mice on a high fat diet showed improved 
insulin resistance compared to wild type mice, as seen through glucose and insulin 
tolerance tests. Additionally, high fat diet-fed IKKε knockout mice have markedly less 
hepatic steatosis and circulating markers of systemic inflammation than wild type mice. 
Interestingly, the targeted deletion of IKKε protects mice against diet-induced obesity, 
while IKKβ deficient mice are not protected. IKKε knockout mice display decreased 
weight gain and adipocyte size, despite increased food consumption, compared to wild 
type mice after 3 months of high fat diet. White adipose tissue from mice had decreased 
adrenergic signaling ex vivo. Pharmacological inhibition of IKKε and TBK1 using the 
selective inhibitor, amlexanox, recapitulated the IKKε knockout phenotype (Chiang, 
unpublished). Amlexanox treatment increased oxygen consumption and lipolysis in 3T3-
L1 adipocytes as well. Finally, inhibitors of IKKε and TBK1 promoted adipogenesis in 
3T3-L1 adipocytes. Together, these studies suggest that IKKε and TBK1 suppress 
energy expenditure and adipocyte development. 
The first figures from this chapter come from a paper published in 2009 (288) and 
a manuscript recently accepted (292), both of which include me as an author. These 
figures provide the necessary background to understand the significance of subsequent 




Figure 2.1 HFD Increases IKKɛ Activity in White Adipose Tissue (A) qPCR analysis on 
the expression of genes encoding IKK family members in liver and white adipose tissue. 
White bars, wild-type mice, normal diet (ND) (n = 6); gray bar, wild-type mice, high-fat 
diet (HFD) for 4 months (n = 6). All data are presented as the average ± SEM 
normalized to Rplp0 expression. Average of ND value was set as 1. (B) qPCR analysis 
on the expression of genes encoding IKK family members in isolated adipocytes and 
stromal vascular fraction. White bars, ND (n = 6); gray bar, HFD for 4 months (n = 6). 
(C) Lysates from white adipose tissue (WAT) of wild-type (WT) and IKKɛ knockout mice 
(IKKɛ KO) fed with ND or HFD were blotted with antibody against IKKɛ as indicated. The 
expression level of IKKɛ was determined by immunoblotting with same antibody against 
IKKɛ. (D) Lysates from WAT of WT and IKKɛ KO fed with ND or HFD were 
immunoprecipitated (IP) with antibody against IKKɛ and assayed for kinase activity 
against myelin basic protein (MBP) as substrate. The expression level of IKKɛ in IP was 
determined by immunoblotting with same antibody against IKKɛ. Lysates for IP were 
immunoblotted against Caveolin 1 as a loading control. 





High-Fat Diet Increases IKKɛ Expression in White Adipose Tissue (288) 
Our lab discovered that a high fat diet induces NFκB activity and the expression 
of IKKε in white adipose tissue (WAT) of wild type mice (288). Using a NFκB responsive 
promoter luciferase mouse, high fat diet produced a two-fold increase in reporter 
activity, which was traced back to 5 fold increase in adipose tissue from epididymal and 
subcutaneous fat depots (data not shown). Macrophage infiltration and adipose “crown-
like” structures appeared with long-term high fat diet. Staining for markers of NFκB was 
enriched in these structures as well.  Together, these experiments showed that 
macrophage infiltration and NFκB activity in adipose tissue is highly correlated with 
obesity.  
Since NFκB is known to control the transcription of IKKε (271), we measured the 
expression of IKKɛ in epididymal white adipose tissue by real-time PCR and then 
compared this to the levels of other IKK family members. HFD produced a small 
increase in the expression of IKKα, β, and TBK1 in liver, but it produced a 2.6-fold 
increase in IKKɛ mRNA (data not shown). In white adipose tissue (WAT), IKKα was 
reduced, whereas HFD induced IKKβ 1.7-fold, and IKKɛ and TBK1 by 12- and 9-fold, 
respectively (Fig 2.1A). To determine which cell types in adipose tissue were 
responsible for these changes, we collagenase digested WAT and separated 
adipocytes from the stromal vascular fraction (SVF), and examined expression of IKK 
family members. HFD produced a 2- to 3-fold increase in expression of IKKα, IKKβ and 
TBK1 mRNA in adipocytes, whereas IKKɛ expression was increased 28-fold (Figure 




number of macrophages in adipose tissue was also significantly increased. Therefore, 
IKKε and TBK1 are transcriptionally upregulated in liver and adipose tissue. We also 
monitored IKKɛ protein levels by western blotting (Figure 2.1C). IKKɛ expression was 
low in WAT from wild-type mice on a chow diet, but was markedly increased in after 
HFD, correlating well with RNA levels. In addition to protein levels, immunoprecipitated 
in vitro IKKɛ kinase activity in WAT from HFD mice was increased by 1.5-fold compared 





Figure 2.2 IKKɛ KO Mice Are Protected from Diet-Induced Weight Gain by Increasing 
Energy Expenditure.(A) Body weight measured for WT, ND (orange); IKKε KO, ND 
(green); WT, HFD (red) and IKKε KO, HFD (blue) during 15 weeks-period (n=10-12 in 
each group). (B) Oxygen consumption (VO2) was measured for WT (orange) and KO 
(green) mice fed with ND (top) or WT (red) and KO (blue) mice fed with HFD (bottom) 
for three days as indicated. n = 8 mice per group (C) Rectal temperature measured for 
WT and KO mice fed with ND (3 months old) or HFD (5 months old with diet for 2 
months). n = 10 per group. *p value < 0.05; ∗∗, p value < 0.01 (D) qPCR analysis on the 
expression of genes encoding UCP1 in WAT. Gray bars, wild-type mice (n = 6); black 
bar, IKKɛ KO mice (n = 6) fed with ND or HFD as indicated. All data are presented as 
the average ± SEM normalized to Rplp0 expression.∗, p value < 0.05. Average of WT 
fed with ND value was set as 1. (E) Protein expression of UCP1 in WAT, measured by 
immunoblotting with WAT lysates from WT and IKKɛ KO mice (5 mice in each group) 
fed with HFD as indicated. Rab5 was used as internal loading control. Data were 




IKKɛ Knockout Mice Display Decreased Weight Gain and Increased Energy 
Expenditure on a High-Fat Diet 
The increased expression of IKKɛ in wild type mice on a high fat diet led us to 
examine if IKKε affects obesity and insulin resistance. We therefore evaluated mice with 
a targeted deletion in the IKKɛ gene (287) on a high-fat diet and examined its metabolic 
phenotype. On normal chow, body weights did not differ significantly between IKKɛ 
knockout mice and wild-type mice. However, after 3 months of HFD, wild-type controls 
gained near 20 g, whereas IKKɛ knockout mice gained only 12 g (Figure 2.2A).  
Body weight represents a balance of food intake and energy expenditure. IKKɛ 
knockout mice showed higher daily food intake per body weight compared to wild-type 
mice, either on chow or HFD (data not shown). Therefore, total caloric consumption 
between wild type and IKKε knockout mice was not different. Oxygen consumption was 
similar in both wild-type and IKKɛ knockout mice on a chow diet (Figure 2.2B). Wild-type 
mice on HFD showed little change in oxygen consumption, whereas IKKɛ knockout 
mice demonstrated a significant increase. This difference was consistent throughout 
light and dark phases, indicating an increase in energy expenditure.  
There were small decreases in respiratory quotient between normal diet and 
high-fat diet mice, indicative of high-fat diet composition (data not shown). High 
respiratory quotient, indicating carbohydrate preference, has been correlated with 
weight gain (293), but no changes in RQ between wild type and IKKε knockout mice 
were observed. Regardless, differences in weight gain could not be attributed to 




The lack of effect of IKKɛ knockout on RQ suggested that there was no 
difference in fuel selection between carbohydrates and lipids, leading us to explore 
whether the increase in energy expenditure may be due to increased thermogenesis, 
and we thus evaluated core body temperature (Figure 2.2C). A significant increase in 
core body temperature was also noted in IKKɛ knockout mice. IKKɛ knockout mice were 
1.5°C warmer than their wild-type counterparts on HFD, with a smaller 0.5°C increase 
seen under chow-fed conditions. In chow-fed mice, UCP1 mRNA was low in WAT from 
wild-type or IKKɛ knockout mice. HFD produced a 2-fold increase in UCP1 mRNA in 
wild-type mice, but generated a 10-fold increase in knockout mice (Figure 2.2D). UCP1 
protein levels in WAT of knockout mice on HFD were similarly higher (Figure 2.2E), 
while mitochondrial proteins and UCP1 mRNA and protein levels in brown fat were 
unchanged (data not shown).  
IKKε knockout mice on a high fat diet showed significantly attenuated increases 
of serum proinflammatory cytokines, such as TNFα, MCP-1, and Rantes compared to 
wild type mice (data not shown). This attenuation of high fat-induced proinflammatory 
responses was also evident in white adipose tissue, where IKKε knockout mice on high 
fat diet had reduced TNFα, Rantes, and MIP1α compared to wild type mice. Decreased 
hepatic steatosis and insulin resistance were also observed in these mice (data not 
shown). 
IKKε and TBK1 Attenuate β-adrenergic-stimulated Glycerol Release in Obesity 
β-adrenergic activation in adipose tissue by either β3 pharmacologic activation or 
cold exposure increases the number of multilocular adipocytes and UCP1 in white 




epididymal fat pads of IKKε knockout mice, we wanted to examine the signaling 
pathways that lead to UCP1 expression and activity. Adrenergic stimuli, such as 
norepinephrine, activate β-adrenergic receptors in white and brown adipose tissue to 
initiate a cascade of events through cyclic AMP (cAMP) culminating in the 
transcriptional upregulation of UCP1, partially through p38, as well as UCP1 activation 
by HSL-liberated free fatty acids, which results in increased proton leak and energy 
expenditure (177, 294). Therefore, we stimulated explants of epididymal white adipose 
tissue with adrenergic stimuli and measured the lipolysis and lipolytic signaling in that 
tissue.  
White adipose tissue from IKKε knockout mice treated with isoproterenol or 
forskolin have increased glycerol release compared to wild type mice (Figure 2.3A). 
Phosphorylation of PKA substrates and HSL were increased in white adipose tissue 
from IKKε knockout mice on a high fat diet as well, indicating increased lipolytic 
signaling paralleled glycerol release (Figure 2.3B,C). Desensitization to adrenergic 
stimuli in adipose tissue is correlated with increases in IKKε and TBK1 expression. 
Studies have shown decreased sensitivity to adrenergic stimuli in adipose tissue as a 
consequence of decreased β-adrenergic receptors on the surface of adipocytes (36) or 
increased expression of α2 adrenergic receptors  (295); however, these forskolin studies 
represent the first time defects beyond the adrenergic receptor account for 
catecholamine resistance. These experiments suggest IKKε and TBK1 are important for 




Fig 2.3 IKKε is Required for Decreases in Lipolytic Signaling in White Adipose Tissue 
(A) Lipolysis from WAT pieces excised from mice fed a high-fat diet treated with 
isoproterenol or forskolin * p-value <0.05 (B) Western blot from WAT pieces excised 
from mice fed a high-fat diet treated with isoproterenol or forskolin (Bottom) Western 
blot from WAT pieces excised from mice fed a high-fat diet treated with isoproterenol or 
forskolin used for part B. 
Mowers J, Unpublished data  
*	  





Figure 2.4: Daily Amlexanox Gavage Prevents Diet-induced Obesity. (A) Body weight of 
preventative group. Mice gavaged with amlexanox at 25 mg/kg (grey squares) or 100 
mg/kg (black squares) or vehicle control (white squares = HFD, white circles = ND). 
Initiation of gavage in the preventative group coincided with high fat diet (HFD) feeding 
at 8 weeks of age (n=5 per group). (B) Oxygen consumption (VO2) of mice in treatment 
group; ND (left panel – light grey circles = vehicle, dark grey circles = 25 mg/kg 
amlexanox) and HFD (right panel – white squares = vehicle, black squares = 25 mg/kg 
amlexanox). (n=4 for ND groups, n=8 for HFD groups). HFD amlexanox treated mean 
values are significantly higher than HFD vehicle mean values during all three light and 
dark cycles, p-value < 0.05. (C) Core body temperature in ND fed mice gavaged with 
vehicle (grey bar), HFD fed mice gavaged with vehicle (white bar) and HFD fed mice 
gavaged with 25 mg/kg amlexanox (black bar). * p-value < 0.05 HFD vehicle control 
versus HFD amlexanox treated or Ob/ob  vehicle control versus Ob/ob amlexanox 
treated. † p-value < 0.05 ND vehicle control versus HFD vehicle control (D) UCP1 
protein levels in WAT of preventative and treatment groups. RalA levels are shown as 
loading controls. 




An Inhibitor of TBK1/IKKε Improves Obesity-related Metabolic Dysfunctions  
In addition to the IKKε knockout mouse, we described amlexanox, a novel 
chemical inhibitor of IKKε and TBK1, that reproduces many of the effects observed in 
the IKKε knockout mouse (292).  Much like the IKKε knockout mouse, administration of 
this compound to mice reduced weight, insulin resistance, inflammation and steatosis in 
three different obese mouse models.  These effects are seen within 3-4 weeks after 
starting drug therapy, and are reversible.  They are likely attributed to increased energy 
expenditure. Importantly, signaling pathways that modulate these processes are 
similarly affected in vitro by addition of amlexanox or other structurally unrelated IKKε 
and TBK1 inhibitors to cultured adipocytes.   
Amlexanox is a selective inhibitor of IKKε and TBK1 
Amlexanox is a selective inhibitor of IKKε and TBK1.  Since deletion of the IKKε gene in 
mice produced partial resistance to the effects of high fat diet (288), our lab screened a 
library of 150,000 chemical compounds to search for inhibitors of IKKε, using 
recombinant baculo-viral expressed, purified full length IKKε, with myelin basic protein 
as substrate, and identified amlexanox as the only verifiable high affinity inhibitor of 
IKKε within the entire library (data not shown).  This previously discovered drug of 
unknown mechanism is used to treat asthma, allergic rhinitis and aphthous ulcers (296). 
Mice Gavaged with Amlexanox Display Decreased Weight Gain and Increased 
Energy Expenditure on a High-fat Diet 
Amlexanox prevents weight gain and causes weight loss when administered to 
genetic or diet-induced obese mice. Because knockout studies previously showed that 




assessed the in vivo effects of amlexanox of mice on a high-fat diet.  C57Bl/6 mice were 
given a diet of 45% fat, and subject to daily gavage with a vehicle control, 25 or 100 
mg/kg amlexanox. Weights of the mice were monitored (figure 2.4A).  Normal chow-fed 
mice on vehicle gavage were used as a lean control. Treatment of animals with either 
dose of amlexanox prevented the weight gain produced by high fat diet; drug-treated 
mice maintained weights equivalent to those of control diet mice throughout 12 weeks.  
Interestingly, there was no effect of the drug on food intake, either at the beginning or 
end of the study (data not shown). 
In addition to preventing obesity, it was important to examine whether amlexanox 
could be used as a bona fide weight loss drug. To determine whether treatment of 
animals with amlexanox could produce weight loss after obesity had been established, 
we fed mice a 45% fat diet for 12 weeks, and then treated them with 25 mg/kg 
amlexanox or vehicle control for 3 weeks (data not shown). Amlexanox produced a 10 
gram weight loss after only 4 weeks of treatment, with no further effect thereafter.  
Moreover, escalation of the dose at this point was without further effect on weight.  To 
determine whether the effects of the drug were reversible, we withdrew the drug after 8 
weeks of treatment and then continued mice on vehicle control.  Mice quickly regained 
the weight that had been lost, returning to control weights after 6-8 weeks.  Weight loss 
during the treatment phase was accompanied by more than a 6 gram reduction in 
overall mass of adipose tissue. Not only did these studies establish that IKKε and TBK1 
are required for maintaining adiposity, but they also showed that the beneficial effects of 




Because there was no effect of amlexanox on food intake (data not shown), we 
reasoned that the weight loss was due to increased energy expenditure.  We thus used 
metabolic cages to monitor energy expenditure in high-fat diet mice treated with or 
without amlexanox. Four-week treatment with 25 mg/kg amlexanox resulted in 
significantly increased oxygen consumption as compared to vehicle control, which is 
consistent with an increase in energy expenditure (Figure 2.4B). The respiratory 
quotient was similar between mice fed a high-fat diet with or without amlexanox 
treatment (data not shown). Therefore, differences in adiposity cannot be explained by 
differences in substrate preference. 
These data suggested that amlexanox might induce an increase in 
thermogenesis. Amlexanox treatment produced an approximate one degree increase in 
body temperature compared to HFD vehicle-treated mice (Figure 2.4C). The levels of 
UCP-1 protein were also increased in the adipose tissue of amlexanox-treated mice as 
compared to HFD vehicle-treated controls in both the treatment and prevention groups 
of mice (Figure 2.4D). In adipose tissue from HFD-fed mice, hormone sensitive lipase 
phosphorylation was reduced, consistent with the well-established desensitization of the 
β-adrenergic pathway in this tissue during obesity.  Interestingly, amlexanox treatment 
prevented the reduction in HSL phosphorylation associated with HFD (Figure 2.4D). 
Hyperinsulinemic-euglycemic clamp studies revealed that free fatty acid levels in 
amlexanox treated animals were higher than untreated animals (data not shown). 
However, the anti-lipolytic effect of insulin on serum free fatty acid levels was more 




Effects of Amlexanox on 3T3-L1 Adipocytes 
The mixed phenotype of increased lipolysis and increased insulin sensitivity led 
us to examine which of these effects are present in cell culture. Treating 3T3-L1 
adipocytes with amlexanox increased lipolysis in a dose dependent manner (data not 
shown). Interestingly, high doses of amlexanox were able to override the anti-lipolytic 
effects of insulin. Moreover, amlexanox increased oxygen consumption in 3T3-L1 
adipocytes to the same degree that forskolin does (data not shown). By using an 
inhibitor structurally unrelated to amlexanox, CAY10576 (297), we showed that IKKε 
and TBK1 were required for insulin stimulated glucose uptake (data not shown). This 
result was also repeated with amlexanox (Maeran Uhm, unpublished data). Therefore, 
there is more data to suggest that IKKε and TBK1 are required to suppress lipolysis and 
promote anabolic pathways, as amlexanox treatment of 3T3-L1 adipocytes demonstrate 
that amlexanox is a lipolytic agent and not an insulin sensitizer. Therefore, we propose 
that the in vivo administration of amlexanox may lead to reduced weight and adiposity 
by increasing lipolysis and that the insulin sensitization is likely a secondary effect of 
increased energy expenditure. 
Since inhibitors of IKKε and TBK1 promote lipolysis, we examined 3T3-L1 
adipocytes in an IKKε and TBK1 inflammatory context to see if IKKε and TBK1 were 
required to decrease lipolytic signaling. 3T3-L1 adipocytes treated with TNFα for 24 
hours dose dependently increased IKKε expression and TBK1 phosphorylation (Figure 
2.5 left). PPARγ levels also decreased in a dose dependent manner, similar to several 




of hormone sensitive lipase in 3T3-L1 adipocytes treated with TNFα for 24 hours to 











Figure 2.5 IKKε and TBK1 are induced by TNFα and Decrease β-adrenergic signaling 
(Left) Western blot of 3T3L1 adipocyte treated with different doses of TNFα for 24 hours 
(Right) Western blot of 3T3L1 adipocyte treated with 50ng/ml of TNFα for 24 hours 
followed by 1 hour pretreatment of different doses of amlexanox, then 15 minutes with 




Inhibitors of IKKε and TBK1 Promote Adipogenesis in 3T3-L1 Adipocytes 
The above studies done in our lab showed that IKKε genetic deletion or 
pharmacologic inhibition of IKKε and TBK1 using amlexanox resulted in increased 
energy expenditure, as measured by oxygen consumption. Surprisingly, the IKKε 
knockout mice have increased adipocyte numbers in their fat pads (288). Adipocyte 
hyperplasia exists in IKKε knockout mice despite the knockout mice being leaner. The 
adipocytes from IKKε knockout mouse were smaller than wild-type adipocytes, which 
agrees with the improved metabolic health of the animals. However, the increased 
adipocyte number is counterintuitive for a lean mouse, as adipocyte hyperplasia 
normally occurs in obese animals (298). High fat diet promotes hyperplasia when 
adipocyte hypertrophy is insufficient to store excess calories from overnutrition. The 
signals that trigger proliferation of preadipocytes are not fully understood. 
Studies in 3T3-L1 adipocytes have emphasized a role for cAMP early in 
adipocyte differentiation (153). cAMP stimulates CREB early in adipocyte differentiation 
to result in C/EBPβ expression (154). Wnt signaling inhibits adipocyte differentiation 
3T3-L1 cells by suppressing PPARγ and C/EBPα expression (147). cAMP results in 
methylation of the Wnt10b, preventing Wnt10b expression (155). The ability of cAMP to 
promote C/EBPβ expression and downregulate Wnt10b are partly responsible for the 
initiation of adipogenesis.  
Since adipogenesis requires cAMP in early stages of adipocyte differentiation, 
we hypothesized that IKKε may inhibit adipogenesis by downregulating cAMP levels. To 
address this hypothesis, we treated 3T3-L1 fibroblasts with inhibitors of IKKε and TBK1 




of IKKε and TBK1 with different chemical structures were able to increase 3T3-L1 
differentiation in a dose dependent manner as shown by oil red O staining (Figure 2.6A) 
and bright field microscopy (data not shown), whereas these compounds were toxic to 
cells at doses ten times higher than the optimal differentiation concentration (data not 
shown). These studies indicate that inhibitors of IKKε and TBK1 may upregulate 





Fig 2.6: Inhibitors of noncanonical IKKs Substitute for IBMX in 3T3-L1 Differentiation (B) 
Oil red O staining of 3T3-L1 adipocytes differentiated with IBMX or with the TBK1/IKKe 






The phenotypes of the IKKε knockout mice and the amlexanox treated mice 
converge on a similar phenotype. Both the IKKε knockout mouse and the amlexanox 
treated mice have reduced weight gain, systemic inflammation, hepatic steatosis, and 
insulin resistance on a high-fat diet compared to wild type or vehicle gavaged mice, 
respectively. The consistent phenotypes of both genetic ablation and pharmacologic 
inhibition in vivo suggest the same mechanism may govern both phenotypes. 
Due to the long time course of obesity development, as well as the many 
comorbid phenotypes of obesity, it is difficult to establish the definitive cause-and-effect 
sequence of events that control the development of obesity and insulin sensitivity in the 
IKKε knockout and amlexanox treated mice. It is possible that the amelioration of 
systemic inflammation prevents metabolic dysfunction in a variety of tissues. However, 
it is more likely that the decreases in systemic inflammation in the IKKε knockout and 
amlexanox-treated mice are secondary to the decreased weight gain. The 
improvements seen in hepatic steatosis may also be secondary to weight reduction in 
the IKKε knockout and amlexanox treated mice. Improved insulin sensitivity in the IKKε 
knockout and amlexanox treated mice is almost certainly not the singular primary effect 
resulting in weight reduction, because insulin is a powerful anabolic hormone. However, 
we cannot rule out that improvements in hepatic steatosis, insulin sensitivity, or 
systemic inflammation may be responsible for weight reduction.  
This was the first time IKKε or TBK1 were observed in adipose tissue since the 




increased expression of IKKε and TBK1 in adipose tissue were somewhat expected 
because NFκB is known to be involved in adipose tissue inflammation (255), and NFκB 
is known to increase IKKε expression (275). The dramatic increase in IKKε levels in 
isolated adipocytes over other tissues implies that the phenotype of the knockout may 
be mediated by adipocytes. This is important because inflammation in adipose tissue 
due to high fat feeding has been linked with macrophage and liver function as well; 
however, transcriptional regulation of IKKε in macrophages or liver was not nearly as 
robust as it was in adipocytes.  
 In addition to increased transcription of IKKε, protein levels and kinase activity 
were also increased in adipose tissue on a high fat diet (Fig 2.1C,D). Subsequent 
studies showed that high fat diet also induced protein levels of TBK1 in adipose tissue 
(data not shown), and that both IKKε and TBK1 were upregulated in brown adipose 
tissue on a high fat diet (data not shown). IKK family members are activated by 
phosphorylation on activation loop serine residues. Whereas high fat diet increases 
IKKε kinase activity immunoprecipitated from adipose tissue, activation of IKKε kinase 
activity is not dramatically upregulated when normalized to total immunoprecipitated 
protein. Instead, IKKε activity correlates with IKKε protein induction. Therefore, IKKε 
protein levels serve as an indicator of kinase activity in the context of diet-induced 
obesity in adipose tissue. 
Crosstalk between adipose tissue and infiltrating macrophages is an active area 
of research (299). Interestingly, mice bearing a macrophage-specific knockout of IKKβ 
are insulin sensitive on a high fat diet, suggesting that insulin resistance in adipose 




many macrophage proinflammatory cytokines, such as TNFα, it is tempting to suggest 
that macrophages release TNFα, which in turn stimulates the NFκB pathway in 
adipocytes to upregulate IKKε and TBK1 (275). 
What is the role of IKKε and TBK1 in adipose tissue? IKKε and TBK1 were 
initially characterized as activators of NFκB due to their ability to phosphorylate IκB in 
vitro (290). However, the current model of IKKε and TBK1 action is quite different. 
Recent studies highlight the crosstalk that exists in IKK family signaling (276). It is now 
thought that IKKε and TBK1 may be involved in a feedback loop to attenuate NFκB by 
reducing the activation of IKKβ. 
 IKKε and TBK1 may influence inflammation in adipose tissue in a manner similar 
to immunologic tissues. The common perspective in obesity is that inflammation, 
mediated partly by NFκB, in adipose tissue is detrimental to human health because it 
promotes insulin resistance, leading to type 2 diabetes and the cardiovascular 
complications that accompany chronic high blood sugar (255). Since dogma within the 
field partially attributes insulin resistance to NFκB inflammation in adipose tissue (255), 
inhibition of IKKε action in adipose tissue could potentially result in greater NFκB 
activation and, therefore, more insulin resistance. However, that is not the phenotype 
we observe in the IKKε knockout mouse, which has decreased inflammatory markers 
both systemically and in adipose tissue with decreased insulin resistance. 
Other studies have called into question the role of NFκB in adipose tissue. 
Constitutive activation of IKKβ in adipose tissue prevents diet-induced obesity in mice 




to increased insulin sensitivity, which was attributed to improvements in body weight via 
increased energy expenditure (302). In contrast to the IKKε knockout mouse or inhibitor 
studies of IKKε and TBK1, constitutive adipose expression of p65 led to a defect in 
adipogenesis both in vivo and in vitro. Although these transgenic systems may not 
represent physiologic activation of the IKKβ—NFκB system, these studies do not 
support the notion that NFκB promotes obesity. Instead, IKKε and TBK1 may inhibit 
IKKβ to decrease NFκB and promote obesity. 
Interestingly, administration of amlexanox led to weight reduction both before and 
after the onset of obesity. Amlexanox appears to be a relatively safe drug with long 
history of use in patients with asthma, allergic rhinitis and aphthous ulcers (303). As 
such, there might be an interesting opportunity for repurposing this agent for diabetes 
and obesity. Furthermore, sustained treatment using amlexanox may be necessary to 
maintain its beneficial effects. While not providing a permanent solution to obesity, 
treatment with amlexanox may be part of a series of sustained therapeutic interventions 
to combat obesity. Future clinical studies will be needed to explore this possibility and to 
validate the hypothesis that these noncanonical IκB kinases contribute to counter-
inflammatory actions that sustain metabolic disease. 
Although the precise mechanisms by which IKKε and TBK1 promote obesity in 
rodents remain to be completely elucidated, most of the evidence points to an important 
role of IKKε and TBK1 in decreasing energy expenditure while increasing fat storage. 
We propose that IKKε and TBK1 inhibit sympathetic activation of adipose tissue. 
Decreased sympathetic activation of adipose tissue due to impaired catecholamine 




is commonly associated with blunted whole-body catecholamine-induced lipolysis (99).  
This is thought to occur through a number of mechanisms, including leptin resistance 
(234), as well as the reduced expression of β (36) or increased expression of α2 
adrenergic receptors  (295). White adipose tissue and cultured isolated adipocytes from 
obese human and mouse models exhibit decreased cAMP-stimulated lipolysis and fat 
oxidation, due to reduced energy expenditure from decreased mitochondrial uncoupling 
(294). Desensitization to adrenergic activation is also a feature of childhood onset 
obesity (28, 29), and has also been observed in adipocytes from first-degree relatives of 
obese subjects (30).  
The IKKε knockout and amlexanox treatment phenocopy traits from mice treated 
with β-agonists or exposed to cold temperatures (165). Elevated energy expenditure in 
these mice suggest increased sympathetic activation, as does increased core body 
temperatures and UCP1 levels in adipose tissue. Interestingly, ex vivo forskolin 
treatment of adipose tissue from mice on a high fat diet suggest that defects in β-
adrenergic signaling and PKA activation exist beyond the level of the β-adrenergic 
receptor. 
This series of studies also demonstrates that IKKε and TBK1 inhibit adipocyte 
differentiation. Increased adipogenesis in 3T3-L1 differentiation correlates well with the 
adipocyte hyperplasia observed in the IKKε knockout mouse (288). The ability of IKKε 
and TBK1 inhibitors to substitute for IBMX in adipogenesis suggest that IKKε and TBK1 
repress cAMP. One possibility is that induction of IKKε and TBK1 serve to reduce levels 
of cAMP, which is important for the suppression of Wnts and upregulation of the 




In summary, we demonstrated that IKKε and TBK1 suppress energy expenditure 
and β-adrenergic signaling both in vivo and in vitro in adipocytes. We investigate the 




Materials and Methods 
Reagents. All chemicals were obtained from Sigma-Aldrich unless stated otherwise. 
Anti-IKKε, anti-TBK1, Phospho-TBK1 (ser172), anti-HSL, phospho-HSL (ser563 or 
ser660), and anti-PPARγ antibodies were purchased from Cell Signaling.  Anti-RalA 
antibody was obtained from BD Bioscience. Anti-flag antibody was obtained from 
Sigma. Anti-UCP1 antibody was obtained from Alpha Diagnostics.  Enhanced 
chemiluminescence (ECL) reagents were purchased from NEN, Inc. EDTA-free 
protease inhibitor tablet was purchased from Roche, Inc.  Amlexanox was purchased 
from Ontario Chemical Inc. (Guelph, Ontario, Canada). TBK1/IKKε inhibitor CAY10576 
was purchased from Cayman Chemical (Ann Arbor, MI). 
Animals and animal care. Wild type male C57BL/6 mice were fed a high fat diet 
consisting of 45% of calories from fat (D12451 Research Diets Inc.) starting at 8 weeks 
of age for 12-24 weeks, while normal diet C57BL/6 controls were maintained on normal 
chow diet consisting of 4.5% fat (5002 Lab Diet).  For the prevention groups, amlexanox 
(25 mg/kg or 100 mg/kg) administration was begun concurrently with HFD feeding at 8 
weeks of age.  For the treatment groups, 25 mg/kg amlexanox treatment was begun at 
20 weeks of age after 12 weeks of HFD. Animals were housed in a specific pathogen-
free facility with a 12-hour light/12-hour dark cycle and given free access to food and 
water.  All animal use was in compliance with the Institute of Laboratory Animal 
Research Guide for the Care and Use of Laboratory Animals and approved by the 





Energy expenditure and respiratory quotient. C57Bl6 mice in the amlexanox treatment 
group were placed in metabolic cages.  The University of Michigan Animal Metabolic 
Phenotyping Core measured oxygen consumption (VO2), carbon dioxide production 
(VCO2) and spontaneous motor activity during 3 consecutive days using the 
Comprehensive Laboratory Monitoring System (CLAMS, Columbus Instruments), an 
integrated open-circuit calorimeter equipped with an optical beam activity monitoring 
system.  The respiratory quotient was calculated by dividing carbon dioxide production 
by oxygen consumption.  The mean values for light and dark cycles were used to 
analyze statistical significance.. 
Core body temperature.  Rectal temperature measurements were performed using a 
YSI 4600 Precision thermometer (YSI, Inc., Yellow Springs, OH). 
Cell culture and transfection. 3T3-L1 fibroblasts (American Type Culture Collection, 
Manassas, Virginia) were cultured and differentiated as described previously (305). 
Cells were routinely used within 7 days after completion of the differentiation process; 
only cultures in which >90% of cells displayed adipocyte morphology were used. 
Western analysis. Tissues were homogenized in lysis buffer (50mM Tris, pH7.5, 5mM 
EDTA, 250mM sucrose, 1% NP40, 2mM DTT, 1mM sodium vanadate, 100mM NaF, 
10mM Na4P2O7, and freshly added protease inhibitor tablet), then incubated for one 
hour at 4 °C (288).  Crude lysates were then centrifuged at 14,000 x g for 15 minutes 
twice and the protein concentration was determined using BioRad Protein Assay 
Reagent. Samples were diluted in sodium dodecyl sulfate (SDS) sample buffer.  Bound 




nitrocellulose membranes (BioRad).  Individual proteins were detected with the specific 
antibodies and visualized on film using horseradish peroxidase-conjugated secondary 
antibodies (BioRad) and Western Lightning Enhanced Chemiluminescence (Perkin 
Elmer Life Sciences). 
IKKε and TBK1 immune-complex kinase assay.  Liver and White adipose tissues were 
collected from C57BL/6 mice on normal chow or high fat diet. Tissues were 
homogenized using Dounce homogenizer with lysis buffer containing 50 mM Tris 
(pH7.5), 150 mM NaCl, 2 mM EDTA, 5 mM NaF, 25 mM β-glycerophosphate, 1 mM 
sodium orthovanadate, 10% glycerol, 1% TritonX-100, 1 mM DTT, and 1 mM PMSF in 
the presence of protease inhibitors (Roche Diagnostics). Tissue cell lysates were 
incubated for 1 hour at 4˚C and cleared by spinning at 13,000 rpm for 15 minutes at 4˚C 
in a table-top centrifuge.  Each 1 mg of lysate was subjected to immunoprecipitation 
using 5 µl of rabbit-polyclonal antibody against TBK1 or IKKε for 1.5 hours at 4˚C.  
Immunocomplexes were harvested by incubation with Protein A beads (Roche 
Diagnostics) for 2 hours at 4˚C.  Immunoprecipitates were extensively washed once 
with lysis buffer and three times with wash buffer containing 20 mM HEPES (pH 7.4), 50 
mM NaCl, 20 mM β-glycerophosphate, 1 mM sodium orthovanadate, 5 mM NaF, 10 mM 
MgCl2, and 1 mM DTT.  An in vitro kinase assay using the immunoprecipitated kinases 
was performed as described above.  Relative levels of MBP phosphorylation were 
detected by autoradiograph and normalized to the levels of IKKε or TBK1 kinase 






Chapter III:  
Inflammation Produces Catecholamine Resistance in Obesity 
Via Activation of PDE3B by the Protein Kinases IKKε  and 
TBK1 
Abstract 
Obesity produces a chronic inflammatory state involving the NFκB pathway, 
resulting in persistent elevation of the noncanonical IκB kinases IKKε and TBK1. In this 
study, we report that these kinases attenuate β-adrenergic signaling in white adipose 
tissue. Treatment of 3T3-L1 adipocytes with specific inhibitors of these kinases restored 
β-adrenergic signaling and lipolysis attenuated by TNFα and Poly (I:C). Conversely, 
overexpression of the kinases reduced induction of Ucp1, lipolysis, cAMP levels, and 
phosphorylation of hormone sensitive lipase in response to isoproterenol or forskolin. 
Noncanonical IKKs reduce catecholamine sensitivity by phosphorylating and activating 
the major adipocyte phosphodiesterase PDE3B. In vivo inhibition of these kinases by 
treatment of obese mice with the drug amlexanox reversed obesity-induced 
catecholamine resistance, and restored PKA signaling in response to injection of a β-3 
adrenergic agonist. These studies suggest that by reducing production of cAMP in 






Obesity generates a state of chronic, low-grade inflammation in liver and adipose 
tissue accompanied by macrophage infiltration and the local secretion of inflammatory 
cytokines and chemokines that attenuate insulin action, resulting in insulin resistance 
and the subsequent development of Type 2 diabetes (1, 255, 256, 299). Numerous 
studies indicate a strong correlation between inflammation and insulin resistance across 
several populations (1). Moreover, genetic ablation or pharmacological inhibition of 
inflammatory pathways can dissociate obesity from insulin resistance (1, 255), 
suggesting that local inflammation can be a key step in the generation of insulin 
resistance. 
The transcription factor NFκB and its inflammatory program play an important 
role in the development of insulin resistance in obese liver and adipose tissue (288, 
300, 306, 307). NFκB is activated by the IκB kinase (IKK) family, which has four 
members: IKKα, IKKβ, IKKε, and TBK1. IKKα and IKKβ act with the scaffolding partner 
NEMO to activate NFκB (259). Although pharmacologic inhibition or genetic ablation of 
IKKβ defined a role for this kinase in insulin resistance (300, 307), the roles of the 
noncanonical kinases IKKε and TBK1 are less certain. 
We recently reported that both mRNA and protein expression levels of IKKε and 
TBK1 are increased in adipose tissue from mice fed a high fat diet (288). Both of these 
kinases are increased as a consequence of the inflammatory program in obesity (292), 
and contain NFκB regulatory sites in their promoter regions, allowing them to be 
induced upon NFκB activation (308). Deletion of the IKKε gene rendered mice partially 




insulin resistance, hepatic steatosis, and systemic inflammation (288). We report, in this 
study, that IKKε and TBK1 can desensitize lipolytic signaling in white adipose tissue in 
response to β-adrenergic agonists by phosphorylating and increasing the activity of 
PDE3B, in the process decreasing cAMP levels. Thus, induction of these noncanonical 
IκB kinases might contribute to catecholamine resistance during obesity, and blocking 
their activity has the potential to increase energy expenditure as an anti-obesity and 
anti-diabetes therapy.  
Results 
IKKε and TBK1 Overexpression Decrease Sensitivity to the β-adrenergic/cAMP 
Pathway in 3T3-L1 Adipocytes 
Sympathetic activation of adipose tissue plays a key role in maintaining energy 
balance by stimulating lipolysis and fat oxidation (27). Activation of β-adrenergic 
signaling by either β-adrenergic agonists or cold exposure in white and brown adipose 
tissue initiates a cascade of events through cyclic AMP (cAMP), culminating in the 
transcriptional upregulation of Ucp1, which results in increased proton leak and energy 
expenditure (168). Our previous studies revealed that compared to wild-type (WT) 
controls, IKKε-deficient mice exhibited increased energy expenditure while on a high fat 
diet (HFD), accompanied by increased expression of Ucp1 in white adipose depots 
(288). Interestingly, increased energy expenditure in IKKε-deficient mice was only seen 
in HFD-fed mice (288), suggesting that upon induction of IKKε during obesity, the 
kinase might repress an increased adaptive thermogenic response to overnutrition. To 
explore this possibility, we overexpressed IKKε in 3T3-L1 adipocytes and examined 
Ucp1 gene expression after treatment with the non-selective β-adrenergic agonist, 




gene expression was calculated by normalization of relative Ucp1 mRNA levels in 
treated relative to control samples. Treatment of empty vector-expressing cells with ISO 
or CL-316,243 resulted in a 1.6-fold or two-fold increase in Ucp1 mRNA levels, 
respectively (Figure 3.1A). The induction of Ucp1 gene expression in response to ISO 
or CL-316,243 was blunted when WT IKKε was overexpressed in these cells. However, 
expression of the kinase-inactive mutant of IKKε K38A (287) was less effective, but still 
modestly repressed Ucp1 expression. 
In addition to increased Ucp1 expression, IKKε knockout mice also exhibited 
increased lipolysis and fat oxidation (288), suggesting that decreased lipolysis in 
adipose tissue from obese mice might result in part from increased expression of IKKε 
and TBK1 (288). We thus modeled the obesity-dependent increase in the noncanonical 
IKKs by overexpressing IKKε in 3T3-L1 adipocytes, followed by assay of glycerol 
release in response to ISO or CL-316,243. Although both isoproterenol and CL-316,243 
increased lipolysis in empty vector-expressing cells, overexpression of WT IKKε 
reduced the lipolytic effects of isoproterenol and CL-316,243 by greater than 40%, and 
also reduced basal glycerol release (Figure 3.1B). The reduction in lipolysis by IKKε 
overexpression was accompanied by dramatically reduced phosphorylation of HSL and 
perilipin in response to ISO or CL-316,243 (Figure 3.1C). Expression of the catalytically 
inactive kinase was less effective in blocking lipolytic signaling, although the levels of 
protein achieved by overexpression were lower compared to the WT kinase (Figure 
3.1B,C). Overexpression of TBK1 reduced phosphorylation of HSL in response to 
isoproterenol or the adenylyl cyclase activator, forskolin (Figure 3.1—figure supplement 




adipocytes stimulated with forskolin (Figure 3.1D), as detected by western blotting with 
an anti-phospho-PKA substrate motif antibody. Overexpression of IKKε also repressed 
the phosphorylation of p38 (p-p38) in response to forskolin (Figure 3.1D) or 
isoproterenol (Figure 3.1—figure supplement 1A), whereas overexpression of IKKε 
K38A was without effect (Figure 3.1—figure supplement 1A). While glycerol release is 
likely the result of changes in HSL and perilipin phosphorylation, it is important to note 
that we have not directly assayed whether re-esterification of glycerol intermediates are 
also affected. Taken together, these data suggest that similar to what is observed in 
obesity, overexpression of IKKε or TBK1 can repress lipolytic signaling. The partial 
effectiveness of the kinase-inactive mutants is puzzling, but may reflect their activation 
of endogenous IKKε or TBK1 kinases due to dimerization (309). 
Since PKA signaling is responsible for Ucp1 induction in response to 
catecholamines (175, 310), we explored the possibility that both IKKε and TBK1 might 
reduce β-adrenergic sensitivity of adipocytes by decreasing cAMP levels. IKKε 
overexpression in 3T3-L1 adipocytes reduced by greater than 80% the increase in 
cAMP levels produced by both isoproterenol and forskolin, whereas overexpression of 
IKKε K38A did not (Figure 3.1E). Previous studies have shown that decreased 
sensitivity to adrenergic stimuli in adipose tissue can result from reduced β-adrenergic 
receptors (36) or increased expression of α2-adrenergic receptors (295). These studies 
represent the first demonstration that defects distal to the adrenergic receptor may also 
contribute to catecholamine resistance, and suggest that IKKε and TBK1 can attenuate 
the β-adrenergic/cAMP pathway in response to β-adrenergic stimuli in adipocytes in a 




account for decreased energy expenditure by reducing sensitivity of adipocytes to β-





Figure 3.1: IKKε and TBK1 Overexpression Decrease Sensitivity to the β-
adrenergic/cAMP pathway in 3T3-L1 adipocytes 
(A) Fold increase in Ucp1 expression in 3T3-L1 adipocytes expressing empty vector, 
Flag-IKKε, or Flag-IKKε K38A following treatment with or without 10 µM ISO (black 
bars) or 10 µM CL-316,243 (CL, gray bars) for 4 hr. **p<0.01. Performed in triplicate. 




Flag-IKKε (black bars), or Flag-IKKε K38A (gray bars) treated with or without 10 µM ISO 
or 10 µM CL. *p<0.05 and **p<0.01. Performed in triplicate. (C) Immunoblots of whole 
cell lysates from Figure 3.1B. Results were replicated in triplicate. D.E. stands for dark 
exposure and L.E. stands for light exposure. (D) Immunoblots of whole cell lysates from 
3T3-L1 adipocytes expressing empty vector or Flag-IKKε treated with or without 50 µM 
FSK for 15 min. Results were replicated in multiple experiments. (E) cAMP levels from 
3T3-L1 adipocytes expressing empty vector, Flag-IKKε, or Flag-IKKε K38A treated with 






Supplemental Figure 3.1: IKKε and TBK1 Overexpression Decrease Sensitivity to the β-
adrenergic/cAMP pathway in 3T3-L1 adipocytes 
(A) Immunoblots of whole cell lysates from 3T3-L1 adipocytes expressing empty vector, 
Flag-IKKε, or Flag-IKKε K38A treated with or without 10 µM ISO for 15 min. Results 
were replicated in multiple experiments. (B) Immunoblots of whole cell lysates from 3T3-
L1 adipocytes expressing increasing amounts of Flag-IKKε or Flag-TBK1 treated with or 
without 10 µM ISO (top panel) or 50 µM FSK (bottom panel) for 15 min. Results were 







Prolonged Treatment with TNFα Decreases the Sensitivity of Adipocytes to β-
adrenergic Stimulation in a Manner Dependent on the activity of IKKε and TBK1 
Obesity is accompanied by infiltration of proinflammatory macrophages into 
adipose tissue; these cells secrete inflammatory cytokines, such as TNFα, which 
generate insulin resistance by stimulating catabolic pathways (255, 256). Although 
TNFα is known to increase lipolysis in adipocytes (311-314), there is also evidence of a 
counterinflammatory response in obesity that may serve to repress energy expenditure 
(292, 315-317). We thus used TNFα to model the inflammatory milieu of obese adipose 
tissue in cell culture to determine whether the cytokine might also regulate β-adrenergic 
signaling in this context. While short-term treatment with TNFα augmented the increase 
in cAMP produced by forskolin treatment, this effect declined after 12 hr. After 24 hr of 
exposure, TNFα inhibited the production of the second messenger produced by 
forskolin (Figure 3.2—figure supplement 1A). Thus, the catabolic effects of the 
proinflammatory cytokine TNFα in adipocytes are transient and followed by an inhibitory 
phase. 
Our previous studies revealed that treatment of 3T3-L1 adipocytes with TNFα for 
24 hr induced the expression of IKKε and increased TBK1 phosphorylation at the active 
site in a manner that was dependent on the activity of IKKβ and the NFκB pathway 
(292). We thus wondered whether the repression of β-adrenergic sensitivity produced 
by longer-term treatment with TNFα might be due to increased activity of the 
noncanonical IKKs. Long-term treatment with TNFα repressed the induction of Ucp1 




1B), whereas the expression of IKKε mRNA (Ikbke) was upregulated, as previously 
reported (292). Treatment of 3T3-L1 adipocytes with TNFα for 24 hr decreased glycerol 
release in response to both isoproterenol and forskolin in a dose-dependent manner 
(Figure 3.2A). TNFα treatment also decreased isoproterenol- and forskolin-stimulated 
cAMP production; an effect that was largely rescued by preincubation of cells with the 
selective, but structurally unrelated inhibitors of IKKε and TBK1, amlexanox (Figure 
3.2B) (292) or CAY10576 (Figure 3.2C) (297). 
Isoproterenol-stimulated β-adrenergic signaling was also decreased by treatment 
of cells with TNFα (Figure 3.2D), as manifested by decreased phosphorylation of HSL, 
perilipin, and other proteins recognized by the PKA substrate motif antibody, whereas 
IKKε expression was concurrently upregulated and TBK1 phosphorylation was 
increased by the treatment with TNFα. Pretreatment of 3T3-L1 adipocytes with 
amlexanox also blocked the inhibitory effect of TNFα on isoproterenol-stimulated β-
adrenergic signaling, as determined by western blotting with an anti-phospho-PKA 
substrate motif antibody, anti-phospho-HSL, and anti-phospho-perilipin antibodies 
(Figure 3.2E). Interestingly, phosphorylation of p38 in response to isoproterenol was 
also dramatically augmented by amlexanox in a dose-dependent manner. Previous 
studies showed that the toll-like receptor 3 (TLR3) agonist, Poly (I:C), results in the 
direct activation of IKKε and TBK1 (274, 276, 277, 282). Similar to TNFα, treatment of 
3T3-L1 adipocytes with Poly (I:C) simultaneously reduced stimulation of cAMP 
production, lipolysis and phosphorylation in response to β-adrenergic stimulation (Figure 
3.2—figure supplement 1C–E), and the inhibitory effects of Poly (I:C) on the sensitivity 




to the extent that was observed with TNFα treatment (Figure 3.2E). It is possible that 
Poly (I:C)-induced desensitization of β-adrenergic pathway engages other pathways 
that are not directly regulated by IKKε and TBK1. These results suggest that obesity-
associated inflammation leads to the activation of IKKε and TBK1, which produces 






Figure 3.2: Prolonged Treatment with TNFα decreases the sensitivity of adipocytes to β-
adrenergic stimulation in a manner dependent on the activity of IKKε and TBK1 
(A) Glycerol release from 3T3-L1 adipocytes treated with or without different 
concentrations of TNFα as indicated for 24 hr followed by treatment with or without 10 
µM ISO or 50 µM FSK. **p<0.0001. Performed in quadruplicate. (B) cAMP levels from 




treatment with or without 10 µM ISO or 50 µM FSK in the presence or absence of 
pretreatment of 50 µM Amlexanox (Am). **p<0.0001. Performed in quadruplicate. (C) 
cAMP levels from 3T3-L1 adipocytes treated with or without 100 ng/ml TNFα for 24 hr 
followed by treatment with or without 50 µM FSK in the presence or absence of 
pretreatment of 1 µM CAY10576 (CAY). **p<0.0001. Performed in triplicate. (D) 
Immunoblots of whole cell lysates from 3T3-L1 adipocytes treated with or without 
different concentrations of TNFα as same as Figure 3.2A for 24 hr followed by treatment 
with or without 10 µM ISO or 50 µM FSK. Results were replicated in multiple 
experiments. ‘[’ indicates total HSL. ‘n.s.’ represents non-specific band. Arrow indicates 
CGI-58. (E) Immunoblots of whole cell lysates from 3T3-L1 adipocytes treated with or 
without 50 ng/ml TNFα or 100 µg/ml poly (I:C) for 24 hr followed by treatment with or 
without 10 µM ISO for 15 min in the presence or absence of pretreatment with 
increasing concentrations (0, 10, 50, and 200 µM) of amlexanox for 30 min. Results 





Supplemental Figure 3.2: Prolonged Treatment of inflammatory cytokines decreases the 
sensitivity of adipocytes to β-adrenergic stimulation 
(A) cAMP levels from 3T3-L1 adipocytes treated with or without 100 ng/ml TNFα for the 
indicated amount of time (left panel: 0–12 hr, right panel: 0–24 hr) followed by treatment 
with or without 25 µM FSK. **p<0.01. Performed in duplicate. (B) Relative gene 
expression (top panel: Ucp1, bottom panel: Ikbke) in 3T3-L1 adipocytes treated with or 
without 100 ng/ml TNFα for 24 hr followed by treatment with or without 10 µM ISO or 50 
µM FSK, or 10 µM CL-316,243 for 4 hrs. **P<0.01 and **p<0.0001. Performed in 




with or without 5 µg/ml poly (I:C) for 24 hr followed by treatment with or without 50 µM 
FSK over the course of 75 min. Performed in triplicate. (D) Glycerol release from 3T3-L1 
adipocytes treated with or without different concentrations of poly (I:C) as indicated for 
24 hr followed by treatment with or without 10 µM ISO or 50 µM FSK. **p<0.0001. 
Performed in quadruplicate. (E) Immunoblots of whole cell lysates from 3T3-L1 
adipocytes treated with or without different concentrations of poly (I:C) as same as 
Figure 3.2—figure supplement 1D for 24 hr followed by treatment with or without 10 µM 






IKKε and TBK1 Reduce cAMP Levels Through Activation of PDE3B 
cAMP levels can also be regulated by phosphodiesterases, which cleave the 
second messenger and in the process dampen cAMP-dependent signals. 
Phosphodiesterase 3B (PDE3B) is the major PDE isoform expressed in adipocytes 
(130). Genetic ablation or pharmacological inhibition of PDE3B in cells and in vivo 
revealed an important role for the enzyme in lipid and glucose metabolism (121, 138, 
139). Phosphorylation and activation of PDE3B by insulin in adipocytes is thought to be 
mediated by Akt, and cAMP itself acts as a negative feedback regulator of its own levels 
by promoting PKA-dependent phosphorylation and activation of PDE3B (121). 
Since we observed that cAMP production was impaired in forskolin or 
isoproterenol-stimulated 3T3-L1 adipocytes overexpressing IKKε (Figure 3.1E), we 
examined whether noncanonical IKKs might desensitize adrenergic stimulation through 
increased activity of PDE3B in adipocytes. Pretreatment with a nonspecific 
phosphodiesterase inhibitor, IBMX, in 3T3-L1 adipocytes expressing IKKε or TBK1 
rescued the full stimulation of cAMP production in response to forskolin (Figure 3.3A). 
Interestingly, the selective PDE3B and PDE4 inhibitor, Zardaverine (318), also blocked 
the inhibitory effects of IKKε and TBK1 overexpression on cAMP levels in response to 
isoproterenol and forskolin in 3T3-L1 adipocytes (Figure 3.3B), suggesting an important 
role for PDE3B as a target of the noncanonical IKKs. 
We next examined whether IKKε and TBK1 directly phosphorylate PDE3B to 
regulate cAMP levels. Recombinant TBK1, Akt and PKA were incubated in vitro with [γ- 




PAGE followed by autoradiography. TBK1 directly catalyzed the phosphorylation of 
PDE3B; phosphorylation was also produced by incubation with Akt and PKA, as 
previously reported (137, 319) (Figure 3.3C). IKKε also catalyzed this phosphorylation in 
vitro (data not shown). This increase in phosphorylation produced by in vitro incubation 
with TBK1, IKKε and PKA was also detected when PDE3B was blotted with antibodies 
that recognize the 14-3-3 binding motif (Figure 3.3—figure supplement 1A). When 
purified PDE3B was incubated with the same amount of recombinant TBK1 and 
canonical IKKβ kinases in vitro, phosphorylation of PDE3B by IKKβ was barely 
detectable, indicating a level of specificity in which PDE3B is a better target of the 
noncanonical IKKs (Figure 3.3—figure supplement 1B). This phosphorylation was dose-
dependent with respect to ATP (Figure 3.3—figure supplement 1C). 
To determine whether IKKε can phosphorylate PDE3B in cells, we co-expressed 
IKKε and its inactive mutant K38A with HA-tagged PDE3B in HEK293T cells, followed 
by immunoprecipitation (IP) with anti-HA antibodies. Expression of IKKε in cells caused 
a shift in electrophoretic mobility of PDE3B, and this shift was not detected when IKKε 
K38A was expressed (Figure 3.3—figure supplement 1D). Phosphorylation of PDE3B 
was also detected after expression of IKKε but not its kinase-inactive mutant K38A in 
cells, as detected by blotting with antibodies that recognize the 14-3-3 binding motif. To 
determine whether this molecular shift was dependent on phosphorylation of PDE3B, 
HA-PDE3B was co-expressed in Cos-1 cells along with IKKε, TBK1 or their kinase 
inactive mutants, and HA immunoprecipitates were treated with or without calf intestinal 
phosphatase (CIP). Expression of both of the wild-type kinases reduced the 




phosphatase (Figure 3.3D, compare lane 3, 7 to lane 4, 8). Neither of the kinase-
inactive mutants had an effect (Figure 3.3D, compare lane 5, 9 to lane 6, 10). 
Previous studies suggested that IKKε and TBK1 bind to their respective 
substrates through a sequence that includes a ubiquitin-like domain (ULD) proximal to 
their kinase domain. This domain is highly conserved among the IKK family members, 
and is 49% identical between IKKε and TBK1 (320, 321). To confirm that PDE3B is a 
bona fide substrate of IKKε and TBK1, we prepared a GST-ULD domain fusion protein 
from TBK1 and incubated this fusion protein with 3T3-L1 adipocyte lysates. The fusion 
protein specifically precipitated endogenous PDE3B from these lysates (Figure 3.3—
figure supplement 1E). To explore further the interaction of these two proteins, we co-
expressed WT TBK1 and its K38A mutant with HA-tagged PDE3B in HEK293T cells, 
and immunoprecipitated the protein with anti-HA antibodies. Kinase-inactive TBK1 was 
preferentially co-immunoprecipitated with PDE3B, whereas the interaction of PDE3B 
with WT TBK1 was barely detectable (Figure 3.3—figure supplement 1F). These data 
suggest that TBK1 and IKKε associate with substrates such as PDE3B, and 
subsequently dissociate upon phosphorylation. 
Next, to test further the role of PDE3B phosphorylation by IKKε and TBK1 in 
initiating its interaction with 14-3-3β, we prepared a GST-14-3-3β fusion protein which 
was incubated with lysates from HEK293T cells co-expressing TBK1 with PDE3B. 
PDE3B was preferentially pulled down by GST-14-3-3β after phosphorylation by TBK1 
but not by its inactive K38A mutant, whereas GST beads alone enriched neither PDE3B 





Figure 3.3: IKKε and TBK1 reduce cAMP through activation of PDE3B 
(A) cAMP levels from 3T3-L1 adipocytes expressing empty vector, Flag-IKKε, or Flag-
TBK1 treated with or without 50 µM FSK, 250 µM IBMX, or together for 15 min. *p<0.05 
and **p<0.0001. Performed in duplicate. (B) cAMP levels from 3T3-L1 adipocytes 
expressing empty vector, Flag-IKKε, or Flag-TBK1 treated with or without 10 µM ISO or 




Performed in duplicate. (C) 32P phospho-image of in vitro kinase reaction using either 
immunoprecipitated HA-PDE3B from HEK293T cells or 1 µg MBP (myelin basic protein) 
as a substrate with recombinant kinases as indicated. Results were replicated in 
multiple experiments. (D) Immunoblots of immunoprecipitation with anti-HA antibodies 
followed by treatment with or without CIP (top panel) and whole cell lysates (bottom 
panel) from Cos-1 cells co-expressing HA-PDE3B with Flag-IKKε/TBK1 or Flag-
IKKε/TBK1 K38A. D.E. stands for dark exposure and L.E. stands for light exposure. 
Results were replicated in multiple experiments. (E) Immunoblots of GST-14-3-3 
pulldown from HEK293T cells co-expressing HA-PDE3B with Flag-TBK1 or Flag-TBK1 
K38A. Ponceau S staining shows the amount of beads used in GST-14-3-3 pulldown. 






Supplemental Figure 3.3: IKKε and TBK1 interact with PDE3B in a manner dependent 
on the activity of IKKε and TBK1 
(A) Immunoblots of in vitro kinase reaction using either immunoprecipitated HA-PDE3B 
from HEK293T cells or 1 µg MBP (myelin basic protein) as a substrate with recombinant 
kinases as indicated. Results were replicated in multiple experiments. (B) Top panel: 
32P phospho-image of in vitro kinase reaction using either immunoprecipitated HA-
PDE3B from HEK293T cells or 1 µg MBP as a substrate with recombinant kinases as 
indicated. Bottom panel: Immunoblots (IB) of in vitro kinase reaction. Results were 
replicated in multiple experiments. (C) Immunoblots of in vitro kinase reaction using 
immunoprecipitated HA-PDE3B from HEK293T cells as a substrate with recombinant 
MBP-IKKε kinase (rIKKε) using increasing amounts of ATP as indicated. Lane 1: Whole 




3: IP without rIKKε. Results were replicated in multiple experiments. (D) Immunoblots of 
immunoprecipitation with anti-HA antibodies (top panel) and whole cell lysates (WCL, 
bottom panel) from HEK293T cells co-expressing HA-PDE3B with Flag-IKKε or Flag-
IKKε K38A. Results were replicated in multiple experiments. (E) Immunoblots of GST-
TBK1 ULD pulldown from 3T3-L1 adipocytes. Ponceau S staining shows the amount of 
beads used in GST-TBK1 ULD pulldown. Results were replicated in multiple 
experiments. (F) Immunoblots of immunoprecipitation with anti-HA antibodies (left 
panel) and whole cell lysates (right panel) from HEK293T cells co-expressing HA-
PDE3B with Flag-TBK1 or Flag-TBK1 K38A. Results were replicated in multiple 
experiments. The schematic model suggests that TBK1 associates with its substrates in 






IKKε and TBK1 Phosphorylate PDE3B at serine 318, Resulting in the Binding of 
14-3-3β 
To evaluate the regulatory role of PDE3B phosphorylation by IKKε and TBK1, we 
determined which sites are phosphorylated. HA-PDE3B was co-expressed in Cos-1 
cells with IKKε and TBK1, and phosphorylated PDE3B was enriched by IP with anti-HA 
antibodies. Phosphorylation sites on human PDE3B were then determined by LC-
MS/MS mass spectrometry. This analysis revealed that serines 22, 299, 318, 381, 463, 
467, and 503 were phosphorylated by both kinases; there were no differences between 
the kinases (Figure 3.4A). Interestingly, the phosphorylation profile of PDE3B matched 
neither known Akt or PKA profiles (133). However, phosphorylation on serine 299 and 
serine 318 had previously been identified on mouse PDE3B (residues equivalent to 
Serine 277 and 296 in mouse PDE3B) in adipocytes and hepatocytes in response to 
both insulin and forskolin (133). 
While several serine residues are known to be phosphorylated on PDE3B in 
response to stimuli, serine 318 (human) is the best characterized. This residue resides 
in a consensus phosphorylation sequence for both Akt and PKA, and also serves as a 
consensus 14-3-3 binding motif once phosphorylated (133, 137). We thus created a 
Ser318Ala (S318A) mutant of PDE3B, and examined its interaction with a GST-14-3-3β 
fusion protein or by GST-14-3-3 overlay assay. Interestingly, despite incubation with 
TBK1, the phospho-defective, S318A mutant of PDE3B, did not specifically interact with 
GST-14-3-3β, whereas the wild-type protein did (Figure 3.4B,C). In a GST pull-down 
assay, the molecular shift of PDE3B S318A was still detected by western blot (Figure 
3.4B), indicating that phosphorylation of PDE3B by TBK1 on other sites still occurred, 




To examine the functional importance of the phosphorylation of PDE3B at Serine 
318, we overexpressed WT PDE3B and its S318A mutant in 3T3-L1 adipocytes, and 
tested the response of the cells to TNFα. Overexpression of WT PDE3B in cells 
reduced the attenuation of forskolin-stimulated cAMP production and phosphorylation of 
HSL produced by TNFα, whereas PDE3B S318A was ineffective (Figure 3.4D, Figure 
3.4—figure supplement 1A,B). These data suggest that although IKKε and TBK1 can 
phosphorylate PDE3B on several sites, serine 318 may be particularly important in the 
regulation of phosphodiesterase function by promoting the interaction between PDE3B 
and 14-3-3β. More importantly, this residue is the major site mediating the negative 






Figure 3.4: IKKε and TBK1 phosphorylate PDE3B at serine 318, resulting in the binding 
of 14-3-3β 
(A) Summary of sites on PDE3B phosphorylated by IKKε or TBK1 (P-sites) from mass 
spectrometry experiments. (B) Immunoblots of GST-14-3-3 pulldown from HEK293T 
cells co-expressing HA-PDE3B or HA-PDE3B S318A with Flag-TBK1. Ponceau S 
staining shows the amount of beads used in GST-14-3-3 pulldown. Results were 
replicated in multiple experiments. (C) GST-14-3-3 overlay on nitrocellulose membrane 
(top blot) and an immunoblot (IB) of whole cell lysates from HEK293T cells co-
expressing HA-PDE3B or HA-PDE3B S318A with Flag-TBK1 (bottom blot). Results 
were replicated in multiple experiments. (D) cAMP levels from 3T3-L1 adipocytes 
expressing empty vector, HA-PDE3B, or HA-PDE3B S318A treated with or without 100 
ng/ml TNFα for 16 hr followed by treatment with or without 25 µM FSK for 15 min. 





Figure 3.4: Overexpression of PDE3B in 3T3-L1 adipocytes reduces the attenuation of 
forskolin-stimulated β-adrenergic signaling produced by TNFα.  
(A) Immunoblots of whole cell lysates from Figure 3.4D. (B) Top left panel, pHSL and 
total HSL signals in whole cell lysates were quantified and normalized to the basal 
signal (lane 1 in Figure 3.4—figure supplement 1A). The normalized pHSL/total HSL 
ratio is presented as the mean ± SEM of two independent experiments. **p<0.0001 and 
*p<0.05. Top right panel, quantification of total IKKε and RalA signals in whole cell 
lysates was performed as described above. **p<0.0001. Bottom left panel, quantification 




described above. Bottom right panel, quantification of pTBK1 and total TBK1 signals in 





IKKε and TBK1 Phosphorylate PDE3B at serine 318, Resulting in the Binding of 
14-3-3β 
Disruption of sympathetic activation of lipolysis and fat oxidation may play an 
important role in the development and maintenance of increased fat storage in obesity. 
Indeed, while numerous studies have demonstrated catecholamine resistance in obese 
adipose tissue (28, 36, 322-324), the underlying mechanisms remain unclear. To test 
the functional importance of the noncanonical IKKs in maintaining energy balance in 
vivo, we investigated whether the administration of a selective inhibitor of IKKε and 
TBK1, amlexanox, can reverse diet-induced catecholamine resistance in rodents. We 
fed mice a high fat or normal diet, treated them with amlexanox by oral gavage for 4 
days (prior to the point when weight loss is seen), and then gave a single intraperitoneal 
(IP) injection of the β3-adrenergic agonist CL-316,243. Injection of CL-316,243 
stimulated a threefold increase in serum FFA and glycerol levels in both vehicle and 
amlexanox-treated mice on normal diet (ND). The effect of CL-316,243 to increase 
serum FFAs was significantly attenuated in HFD-fed, vehicle-treated mice. However, 
HFD-fed mice treated with amlexanox responded like normal diet mice, despite the fact 
that they were weight matched with control HFD-fed mice (Figure 3.5A). The fold 
increase in serum glycerol levels was also significantly higher in amlexanox-treated 
HFD mice, as compared to vehicle-treated HFD-fed mice. In addition, ex vivo 
pretreatment of white adipose tissues from mice on a HFD with amlexanox enhanced 
glycerol release (Figure 3.5B). This effect was more pronounced in the inguinal fat 
depot, where amlexanox pretreatment increased phosphorylation of HSL, perilipin, and 
other proteins recognized by the PKA substrate motif antibody in response to CL-




also concurrently increased the phosphorylation of TBK1 at Ser172 due to the relief of 
feedback inhibition, as previously reported with other inhibitors (282, 292). 
To examine whether inhibition of TBK1 and IKKε with amlexanox reverses 
resistance to catecholamine-induced lipolysis in vivo by increasing stimulation of cAMP 
production, we measured cAMP levels in epididymal adipose tissue from mice on HFD 
after CL-316,243 IP injection. Interestingly, levels of cAMP were increased after CL-
316,243 IP injection in mice on HFD pretreated with amlexanox (Figure 3.5D). 
Consistent with this, HSL phosphorylation was also increased after CL-316,243 IP 
injection of HFD-fed mice pretreated with amlexanox (Figure 3.5E). 
Our previous studies showed that increased expression of Ucp1 in white adipose 
depots resulted in increased energy expenditure in IKKε-deficient mice (288) and 
amlexanox-treated mice (292) while on a high fat diet but not on a normal diet. To 
examine whether inhibition of catecholamine resistance in obese adipose tissue by 
targeting noncanonical IKKs with amlexanox can lead to increase energy expenditure in 
diet-induced obese mice, we measured oxygen consumption rates of vehicle or 
amlexanox-treated HFD-fed mice after a single injection of CL-316,243 in metabolic 
cages. The effect of CL-316,243 to increase energy expenditure was more pronounced 
in amlexanox-treated HFD-fed mice, as compared to vehicle-treated HFD-fed mice 
(Figure 3.5F). These data suggest that targeting the noncanonical IKKs with the 








Figure 3.5: The IKKε/TBK1 inhibitor Amlexanox sensitizes β-adrenergic agonist-
stimulated lipolysis in white adipose tissue in diet-induced obese mice. 
(A) Fold increase in serum FFA (left panel) and glycerol (right panel) levels 15 min after 
CL-316,243 injection in ND- or HFD-fed mice treated with amlexanox or vehicle control 
for 4 days. n = 7 mice per group. *p<0.05. (B) Glycerol release from ex vivo epididymal 
(left panel) and inguinal (right panel) WATs after 1 hr pretreatment with amlexanox or 




*P<0.05. (C) Immunoblots in inguinal WAT lysates from Figure 5B after 60 min of CL-
316,243 treatment. (D) cAMP levels in epididymal WAT 20 min after CL-316,243 (CL) or 
saline control injection in HFD-fed mice treated with amlexanox or vehicle control for 4 
days. n = 2 mice per saline-treated group and n = 3 mice per CL-316,324-treated group. 
*p<0.05. (E) Immunoblots in epididymal WAT 5 min after CL-316,243 or saline control 
injection in HFD-fed mice treated with amlexanox or vehicle control for 4 days. (F) 
Relative oxygen comsumption of mice in each treatment group. n = 7 for the vehicle-






Decreased sympathetic activation of adipose tissue due to impaired 
catecholamine synthesis or sensitivity has been observed in obese patients (26, 36, 99, 
304). Obesity is commonly associated with blunted whole-body catecholamine-induced 
lipolysis (99). This is thought to occur through a number of mechanisms, including leptin 
resistance (234), as well as the reduced expression of β-adrenergic receptors (36) or 
increased expression of α2-adrenergic receptors (295). White adipose tissue and 
cultured isolated adipocytes from obese human and mouse models exhibit decreased 
cAMP-stimulated lipolysis and fat oxidation, due to reduced energy expenditure from 
decreased mitochondrial uncoupling (294). This desensitization to adrenergic activation 
is also a feature of childhood onset obesity (28, 29), and has been observed in 
adipocytes from first-degree relatives of obese subjects (30). 
We demonstrate here a novel link between obesity and reduced sympathetic 
activity and β-adrenergic sensitivity, through the inflammation-dependent induction of 
the noncanonical IκB kinases IKKε and TBK1. Obesity generates a state of low-grade 
inflammation in both humans and rodents, which involves activation of the NFκB 
pathway (1, 255, 256). Upon its prolonged activation, NFκB induces the expression of 
the noncanonical IκB kinases IKKε and TBK1. The induction of these kinases was 
blocked by administration of anti-inflammatory agents to mice without producing weight 
loss, suggesting that they are expressed in response to inflammation rather than obesity 
per se (292). Deletion of the IKKε gene rendered mice partially resistant to weight gain, 
insulin resistance, steatosis and the long-term inflammation produced by high fat diet 




induced obese or ob/ob mice produced even more profound effects (292). The blockade 
of these kinases in obese rodents with amlexanox results in increased phosphorylation 
of PKA substrates in adipose tissue, along with increased expression of Ucp1, and 
improved rates of lipolysis and fat oxidation (292). Amlexanox was shown to inhibit 
phosphodiesterase activity of rat peritoneal mast cells via an unknown mechanism 
(325). Together these data indicate that IKKε and TBK1 might exert their physiological 
effects in part by reducing the sensitivity of adipocytes to β-adrenergic stimulation via 
changes in cAMP. 
Data presented here suggest that the molecular target of IKKε/TBK1 is the 
phosphodiesterase PDE3B. Upon increased expression in the obese state, these 
kinases can phosphorylate PDE3B, causing an increase in the activity of the enzyme 
that cleaves cAMP, reducing the stimulation of cAMP-dependent phosphorylation of 
proteins in response to sympathetic activation. These proteins include HSL and 
perilipin, responsible for β-adrenergic-stimulated lipolysis, and other proteins such as 
p38 that regulate expression of Ucp1. The reduced sensitivity to β-adrenergic activation 
can attenuate lipolysis and fatty acid oxidation, as well as adaptive thermogenesis. 
Several issues deserve further attention. The first concerns the relative roles of 
the two noncanonical IKKs in this pathway. Both TBK1 and IKKε are induced in 
response to obesity-dependent inflammation, and appear to phosphorylate PDE3B on 
the same residues with equal efficiency. Although there are differences in expression of 
these kinases in other tissues (271), and perhaps differences in the upstream signals 
that lead to their regulation (306), their relative roles in controlling this pathway remain 




While phosphorylation correlates well with decreased levels of cAMP in cells, we have 
been unable to demonstrate increased catalytic activity of the enzyme due to 
phosphorylation by IKKε, TBK1 or the other kinases (137, 319) thought to regulate the 
phosphodiesterase. Perhaps the phosphorylation-dependent binding of the enzyme to 
14-3-3 exerts changes in its localization and access to its substrate, thus explaining 
increased activity in cells. 
How is it that insulin resistance produced by inflammation fails to block continued 
energy storage? One possible explanation may lie in the homeostatic response to 
inflammation itself, typified by the induction of TBK1 and IKKε. Our data confirm 
previous findings that TNFα and perhaps other inflammatory cytokines can promote 
lipolytic processes in cells after short-term treatment, but that after longer exposure elicit 
an inhibitory response that appears to be the result of TBK1 and IKKε induction. Thus, 
these kinases may be part of a ‘counter-inflammatory’ program that attenuates the 
extent to which inflammatory signals are effective, and also serves to conserve energy 
by repressing lipolysis and fatty acid oxidation through activation of PDE3B. 
Interestingly, PDE3B is also a target of insulin action in adipocytes (121). Thus, TBK1 
and IKKε appear to co-opt insulin targets to conserve energy during obesity. These 
insights further suggest that the noncanonical IKKs might be interesting new therapeutic 





Materials and Methods 
Reagents. All chemicals were obtained from Sigma-Aldrich (Saint Louis, MO) unless 
stated otherwise. Anti-Flag antibody was obtained from Sigma, and anti-HA antibody 
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-IKKε, anti-TBK1, 
anti-phospho-TBK1 (Ser172), anti-AKT, anti-phospho-AKT (Ser473), anti-HSL, anti-
phospho-HSL (Ser660), anti-p38, anti-phospho-p38, anti-perilipin, anti-ATGL and anti-
PPARγ antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-
phospho-perilipin (Ser522) was purchased from Vala Sciences Inc (San Diego, CA). 
Anti-CGI-58 was purchased from Novus Biologicals (Littleton, CO). Anti-RalA antibody 
was obtained from BD Bioscience (San Jose, CA). Anti-Ucp1 antibody was obtained 
from Alpha Diagnostics (San Antonio, TX). Anti-PDE3B was provided as a generous gift 
by the Dr Vince Manganiello (NHLBI, NIH). Enhanced chemiluminescence (ECL) 
reagents were purchased from Thermo Scientific (Rockford, IL). EDTA-free protease 
inhibitor tablet was purchased from Roche Diagnostics (Indianapolis, IN). Monoclonal 
anti-HA agarose (Sigma) was used for immunoprecipitations, performed using the 
manufacturer’s protocol. The human PDE3B cDNA was kindly provided by Dr Morris 
Birnbaum (University of Pennsylvania). The human 14-3-3β cDNA was kindly provided 
by Dr Ken Inoki (University of Michigan) and subcloned into pKH3 (326) and pGEX-4T-1 
vectors (GE Healthcare Life Sciences, MI). Amlexanox was purchased from Ontario 
Chemical Inc. (Guelph, Ontario, Canada). The TBK1/IKKε inhibitor CAY10576 was 
purchased from Cayman Chemical (Ann Arbor, MI). 
Cell culture and transfection. 3T3-L1 fibroblasts (American Type Culture Collection, 




were routinely used within 7 days after completion of the differentiation process; only 
cultures in which >90% of cells displayed adipocyte morphology were used. 3T3-L1 
adipocytes were transfected on the second day post FBS using Amaxa Cell Line 
Nucleofector Kit L (Lonza, Houston, TX) according to the manufacturer’s protocol. 3T3-
L1 adipocytes were serum starved for 12 hr with 0.5% fetal bovine serum (FBS) in 
Dulbecco’s modified eagle medium (DMEM, Invitrogen, Grand Island, NY) prior to TNFα 
treatments (50 ng/ml unless otherwise noted). 3T3-L1 adipocytes were pre-treated for 1 
hr with amlexanox at the given concentrations. Alternatively, 3T3-L1 adipocytes were 
treated with 50 µM forskolin or 10 µM isoproterenol for 15 min, after a 60 min 
amlexanox pretreatment. The cells were harvested for total RNA and analyzed by real-
time PCR. Cell lysates were resolved on SDS-PAGE and analyzed by immunoblot using 
the indicated antibodies. HEK293T or Cos-1 cells were cultured to 90% confluence and 
transfected using Opti-MEM media (Invitrogen) and 3 µl Lipofectamine 2000 (Invitrogen) 
per µg DNA according to manufacturer’s protocol. Coexpression of IKKε or TBK1 with 
HA-PDE3B was done using a 2 µg kinase: 1 µg PDE3B ratio of the expression 
constructs. 
Western analyses. Tissues were homogenized in lysis buffer (50 mM Tris, pH 7.5, 5 mM 
EDTA, 250 mM sucrose, 1% NP40, 2 mM DTT, 1 mM sodium vanadate, 100 mM NaF, 
10 mM Na4P2O7, and freshly added protease inhibitor tablet), then incubated for 1 hr at 
4°C (288). Crude lysates were then centrifuged at 14,000 × g for 15 min twice and the 
protein concentration was determined using BioRad Protein Assay Reagent (Bio-Rad, 
Hercules, CA). Samples were diluted in sodium dodecyl sulfate (SDS) sample buffer 




electrophoresis and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). 
Individual proteins were detected with the specific antibodies and visualized on film 
using horseradish peroxidase-conjugated secondary antibodies (Bio-Rad, Hercules, 
CA) and Western Lightning Enhanced Chemiluminescence (Perkin Elmer Life Sciences, 
Waltham, MA). 
Animals and animal care. Wild-type male C57BL/6 mice were fed a high fat diet 
consisting of 45% of calories from fat (D12451 Research Diets Inc., New Brunswick, NJ) 
starting at 8 weeks of age for up to 6 months, while normal diet C57BL/6 controls were 
maintained on normal chow diet consisting of 4.5% fat (5002 Lab Diet, St. Louis, MO). 
Animals were housed in a specific pathogen-free facility with a 12-hr light/12-hr dark 
cycle and given free access to food and water. All animal use was in compliance with 
the Institute of Laboratory Animal Research Guide for the Care and Use of Laboratory 
Animals and approved by the University Committee on Use and Care of Animals at the 
University of Michigan. 
Gene expression analysis. Total RNA was extracted from differentiated 3T3-L1 
adipocytes using the RNeasy Kit (Qiagen, Valencia, CA) with a DNase step. The 
Superscript First-Strand Synthesis System for RT-PCR (Invitrogen, Grand Island, NY) 
was used with random primers for reverse transcription. Real-time PCR amplification of 
the cDNA was performed on samples in triplicate with Power SYBR Green PCR Master 
Mix (Applied Biosystems, Carlsbad, CA) using the Applied Biosystems 7900HT Fast 
Real-time PCR System. Adrp was chosen as the internal control for normalization as its 
expression was not significantly affected by experimental conditions. Sequences of 




‐CTGAGTGAGGCAAAGCTGATTT‐3′. Sequences of Ikbke primers used in this 
study are 5′-ACAAGGCCCGAAACAAGAAAT-3′ and 5′-
ACTGCGAATAGCTTCACGATG‐3′. Data were analyzed using the 2−ΔΔCT method 
(Livak and Schmittgen, 2001). 
In vivo CL-316,243 treatment. Mice were placed on a high fat diet for 6 months, then 
after 1 week of daily gavage with vehicle, mice were gavaged with either vehicle or 
amlexanox (25 mg/kg) daily for 4 days. On the fourth day, mice were injected with CL-
316,243 (1 mg/kg) or saline control. For analysis of blood metabolites, serum samples 
were collected before and 15 min after the injection, via a submandibular bleed. Mice 
were euthanized and WAT samples were collected for cAMP measurement and western 
blot analysis, 15 min or 20 min after injection. Analysis of oxygen consumption was 
performed in metabolic cages, as previously described (292), by the University of 
Michigan Metabolic Phenotyping Core. Relative oxygen consumption was obtained by 
normalization of oxygen consumption rates, after the CL-316,243 injection, to the 
oxygen consumption rates on day 3 in the same mouse after saline injection. Both 
injections were performed at 11 am. 
Ex vivo glycerol release lipolysis assay in white adipose tissue. For experiments 
involving CL-316,243, pieces were pre-incubated for 30 min with amlexanox (100 µM) 
or DMSO vehicle control; then the tissue pieces were transferred to fresh media with 
and without 10 mM CL-316,243, and media samples were collected every 15 min for 1 
hr. To measure glycerol release, 10 µl of supernatant was combined with 200 µl of Free 




incubate for 15 min at room temperature. Absorbance at 540 nm was measured to 
determine glycerol content and was normalized to determine glycerol production per mg 
of white adipose tissue. 
Glycerol release lipolysis assay in 3T3-L1 adipocytes. 3T3-L1 adipocytes were 
incubated in DMEM (Invitrogen) without phenol red for 2 hr at 37°C. The cells then were 
incubated for 90 min at 37°C in HBSS-2% fatty acid-free BSA with 10 µM isoproterenol 
or 10 µM CL-316,243. Free glycerol concentration was measured by reacting 25 µl of 
conditioned media with 200 µl Free Glycerol Reagent (Sigma) and absorbance was 
measured at 540 nm using the manufacturer’s protocol. Glycerol release was 
normalized to cellular protein content. 
cAMP enzyme immunoassay. 3T3-L1 adipocytes were treated with β-agonists and/or 
phosphodiesterase inhibitors and allowed to incubate for the indicated amount of time at 
37°C. The cells were lysed with 150 µl 0.1 M HCl, scraped and spun down. A cAMP 
Enzyme Immunoassay Kit (Sigma CA201) was used to quantify cAMP levels. 50 µl of 
cell lysates was combined with 50 µl Assay Buffer 2 in each well and cAMP levels were 
assayed according to the manufacturer’s protocol. Tissue samples were homogenized 
in 5% TCA, then extracted with water-saturated ether, and dried before resuspension in 
Assay Buffer 2. 
Glosensor cAMP assay in 3T3-L1 adipocytes. 80 µl of packed 3T3-L1 cells was 
electroporated with 3 µg of Glosensor 22-F using Amaxa Cell Line Nucleofector Kit L 
(Lonza) according to the manufacturer’s protocol. Electroporated cells were 




an opaque, white, 96-well tissue culture plate (BD Bioscience, San Jose, CA). After 20 
hr, media were changed to 100 µl DMEM with 1.5 mg/ml luciferin and allowed to 
equilibrate for 1 hr. The cells were treated with 50 µM forskolin and luminescence was 
read every 30 s for 75 min. 
In vitro kinase assays. In vitro kinase assays were performed by incubating purified 
kinase (IKKε, TBK1, IKKβ, PKA, or AKT) in kinase buffer containing 25 mM Tris (pH 
7.5), 10 mM MgCl2, 1 mM DTT, and 10 µM ATP for 30 min at 30°C in the presence of 
0.5 µCi γ-[32P]-ATP and 1 µg myelin basic protein (MBP) per sample as a substrate. 
IKKε and TBK1 were fused to MBP (maltose binding protein) and these fusion proteins 
were purified from insect SF9 cells by baculovirus expression system by Dr Stuart J 
Decker (Life Sciences Institute, University of Michigan). IKKβ, PKA, and AKT kinases 
were purchased from Millipore (Billerica, MA). The kinase reaction was stopped by 
adding 4X sodium dodecyl sulfate (SDS) sample buffer and boiling for 5 min at 95°C. 
Supernatants were resolved by SDS-polyacrylamide gel electrophoresis, transferred to 
nitrocellulose, and analyzed by autoradiography using a Typhoon 9410 phosphorimager 
(GE Life Sciences, Piscataway, NJ). The bands were quantified using ImageQuant. 
Calf-intestinal phosphatase dephosphorylation. Calf intestinal phosphatase (CIP) was 
obtained from New England Biolabs (Ipswich, MA). Immunoprecipitated PDE3B was 
incubated for 1 hr at 37°C in a 100 µl reaction containing 50 mM Tris pH 7.5, 150 mM 
NaCl, 1% NP-40, EDTA-free protease, and 5 µl CIP. 
Protein purification. For assays requiring soluble protein, purified GST-14-3-3β protein 




pH 8.0. The elution was monitored by A280 readings, and fractions containing protein 
were pooled and dialyzed overnight against 4 L of ice-cold PBS. The proteins were then 
concentrated using an Amicon centrifugal filtration unit (Millipore). Concentrated 
proteins were stored at −80°C in PBS containing 10% glycerol and 10 mM DTT. 
GST-14-3-3 Pulldown. For GST-14-3-3 pulldowns, cells were washed twice with ice-
cold PBS and then lysed in 1 ml of 14-3-3 pulldown buffer (PD buffer; 15 mM Tris, pH 
7.5, 150 mM NaCl, 0.5% NP-40, 1 mM DTT) supplemented with a protease inhibitor 
tablet (Roche). Lysates were cleared by centrifuging at 13,000×g for 10 min and then 
were incubated with ~10 mg of GST or GST-14-3-3β bound to glutathione beads (GE 
Healthcare Life Sciences, MI) for 1.5 hr at 4°C. For samples treated with phosphatase, 
lysates were preincubated with 500 U of calf intestinal phosphatase (New England 
Biolabs, Inc.) at 37°C for 1 hr before adding GST-14-3-3 beads. The beads were 
washed three times with 1 ml of PD buffer and then resuspended in 2X SDS sample 
buffer. 
Preparation of DIG-labeled proteins and overlay assay. GST or GST-14-3-3β was 
labeled with DIG by incubating 25 mg of protein with 2 ml of 5 mM Digoxigenin-3-O-
methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester (DIG-NHS; Roche) in 
350 ml of PBS for 15 min at room temperature. The labeling reaction was stopped by 
adding 100 ml of 1 M Tris-HCl, pH 7.4. Labeled protein was dialyzed against 1 L of 25 
mM Tris-HCl, pH 7.4 for 1 hr at room temperature, then against 4 L of PBS, pH 7.4 for 4 
hrs at 4°C, and finally against 4 L of fresh PBS, pH 7.4 for 16 hrs at 4°C. Labeled 




containing 2 mg/ml BSA (Sigma-Aldrich) and 0.01% sodium azide (Sigma-Aldrich). DIG-
labeled proteins were stored at 4°C. 
For overlay assays, PDE3B was immunoprecipitated from HEK293T cells and resolved 
by SDS-PAGE. Proteins were transferred to a nitrocellulose membrane. The membrane 
was blocked at room temperature overnight in blocking buffer (5% skim milk in TBS-T). 
The membrane was then incubated with DIG-labeled proteins for at least 4 hr at 4°C 
and then washed three times with TBS-T. The membrane was then incubated with 
blocking buffer containing anti-DIG HRP antibody (1:10,000; Roche) for 2 hr at room 
temperature, and washed three times with TBS-T. Overlays were visualized by reacting 
with ECL western blotting substrate (Perkin Elmer Life Sciences, Waltham, MA). 
Mass spectrometry. In-gel digestion followed by LC-MS/MS analysis was carried out by 
the mass spectrometry-based proteomics resource in the Department of Pathology, 
University of Michigan. Briefly, tryptic peptides were resolved on a nano-C18 reverse 
phase column and sprayed directly onto Orbitrap mass spectrometer (LTQ-Orbitrap XL, 
Thermofisher). Orbitrap was operated in a data-dependent mode to acquire one full MS 
spectrum (resolution of 30,000@400 m/z) followed by MS/MS spectra on six most 
intense ions (top 6). Proteins were identified by searching data against human protein 
database (Uniprot, rel. 2010-9) using X!Tandem/TPP software suite. Oxidation of Met, 
carbamidomethylation of Cys and phosphorylation of Ser, Thr, and Tyr were considered 
as potential modifications (327). 
Statistical analyses. Averaged values are presented as the mean ± SEM. When 




significance. When more than two groups and two factors were investigated, we first 
performed a two-way analysis of variance (ANOVA) to establish that not all groups were 
equal. After a statistically significant ANOVA result, we performed between-group 
comparisons using the Tukey post hoc analysis for comparisons of all means and Sidak 
for comparisons of within factor main effect means. ANOVA and Tukey/Sidak tests were 






Chapter IV:  
Conclusion 
To Every Metabolic Action, an Opposite Reaction 
The persistence of insulin resistance with obesity creates a paradox. If obese 
animals are rendered insensitive to the anabolic effects of insulin, how is it that an 
anabolic state persists? Why does insulin resistance fail to reverse obesity? Energy 
balance consists of opposing anabolic and catabolic pressures. The body has evolved 
mechanisms to protect against wide fluctuations in body weight, by continually 
counterbalancing anabolic and catabolic processes. However, when faced with 
sustained overnutrition, the I conclude the resolution of these processes eventually 
favors the conserved evolutionary pressure to store energy.  
Our lab studies the link between inflammation in adipose tissue and obesity. 
Through the studies detailed in this thesis, I hope to clarify the role of the IKK family of 
kinases as they relate to adipocyte metabolism. Whereas IKKβ has an established role 
in promoting inflammation in insulin resistance (255), the studies herein establish that 
the counterinflammatory IKK family members, IKKε and TBK1, promote obesity by 
activating PDE3B in adipose tissue. Below, I discuss the molecules that regulate the 
body’s anabolic and catabolic processes and how these processes are altered in the 




TBK1. These ideas are also discussed in a review written by my mentor Dr. Alan Saltiel 
(316). 
Insulin Action 
Insulin is the most important regulator of anabolism (113). Insulin facilitates the 
storage of simple energy molecules, such as simple sugars, amino acids, and fatty 
acids, into complex storage molecules (113). Insulin is released from pancreatic β-cells 
in response to ingested carbohydrates.  Protein or lipids stimulate insulin secretion by 
the action of incretins, such as glucagon like peptide 1 (328). Circulating insulin then 
acts on liver, muscle, and adipose tissue to promote the synthesis and storage of 
glycogen, protein, and triglycerides in these tissues (113). In adipose tissue, insulin 
stimulates adipocyte differentiation and adipose tissue expansion. Insulin’s effects on 
adipose tissue expansion are attributed to its ability to stimulate uptake of free fatty 
acids and glucose, initiate de novo fatty acid synthesis, and inhibit lipolysis.  
As mentioned previously, insulin decreases the lipolytic pathway through a 
variety of targets (see chapter 1). Insulin attenuates lipolysis partly by activating 
phosphodiesterase 3B (PDE3B) (121). Whereas activation of adenylyl cyclase produces 
cAMP, PDE3B is responsible for cleaving cAMP to AMP to terminate β-adrenergic 
pathway signaling in adipose tissue. Therefore, upregulation of PDE3B by hormonal 
cues, such as insulin, promotes anabolic processes and reduces catabolic processes in 
adipose tissue. This is important to highlight, because in chapter 3 I explored the 





A pathogenic model of counterbalancing homeostatic mechanisms in metabolic 
dysfunction is emerging. The progression of metabolic disease in adipose tissue begins 
with overnutrition, prolonged insulin action, and energy storage. As a consequence of 
sustained insulin receptor activation, insulin signaling is downregulated by reduced 
surface expression of the insulin receptor, increased phosphatase activity, and negative 
feedback by S6K through IRS phosphorylation (316). Therefore, acute desensitization 
events may serve as a homeostatic feedback mechanism to prevent insulin signaling, 
but these processes rapidly disappear so that animals can store energy in response to 
the next meal. 
Leptin Action 
Overnutrition leads to multiplication and expansion of adipocytes. Hypertrophied 
adipocytes secrete leptin which acts in the hypothalamus to reduce appetite and 
increase sympathetic activity to counter energy storage and adipose expansion (234). 
Upon leptin binding, the leptin receptor is phosphorylated at Tyr1138 and Tyr985, 
among other sites. Tyr1138 phosphorylation results in activation of STAT3, which 
increases satiety and energy expenditure, and leptin deficient animals have a 
thermogenic defect (235). UCP1 is required for leptin-stimulated reductions in white 
adipose tissue in pair fed mice (236). Therefore, leptin action, like insulin 






When elevated leptin levels are sustained for several days, STAT3 activation in 
the hypothalamus results in the upregulation of SOCS3 to cause leptin resistance (234) 
(329). SOCS3 is recruited to the leptin receptor by phosphorylation of Tyr985 to 
downregulate leptin receptor signaling. Tyr985 phosphorylation also recruits SHP-2 to 
the leptin receptor to downregulate receptor activity through a mechanism that is not 
fully understood. Phosphorylation of Tyr985 of the leptin receptor therefore serves as a 
mechanism by which the body counters the catabolic effects of leptin to favor a positive 
energy balance, despite the presence of insulin desensitization in the short-term. 
Inflammatory Insulin Resistance and β-cell Dysfunction 
Obesity produces a state of chronic, low-grade inflammation in liver and fat 
characterized by macrophage infiltration and the local secretion of inflammatory 
cytokines and chemokines (1, 255, 256). Prolonged adipose expansion leads to the 
release of chemokines, such as MCP-1, that recruit M1-polarized proinflammatory 
macrophages to adipose tissue. These macrophages secrete TNFα and other 
proinflammatory cytokines that trigger inflammatory receptors on adipocytes leading to 
JNK and IKKβ activation to mediate adipocyte resistance to insulin action (289). Many 
of these inflammatory signaling molecules work through IKKβ and NFκB. Circulating 
free fatty acids, interleukin 1, TNFα, advanced glycated end products, glucosamine, and 
ER stress have all been linked to NFκB in insulin resistance (257).  
Resistance to insulin action in this inflammatory context occurs through some of 
the same insulin targets that non-inflammatory desensitization occurs. For example, 




facilitated by the action of JNK, IKKβ, and PKC isoforms in the obese state (330). 
Additionally, PPARγ is negatively regulated at the transcriptional and post-
transcriptional level by the action of inflammatory kinases in adipocytes (289). The 
inability of adipose tissue to store fatty acids via PPARγ results in lipid overflow into 
circulation and the deposition of lipid in other tissues. Fatty acids are ectopically 
deposited in muscle and hepatic tissue, which further desensitizes the body to the 
action of insulin. Adipocytes can therefore regulate whole-body insulin sensitivity either 
directly in adipose tissue, or indirectly through the action of free fatty acids on muscle 
(289). In sum, Inflammation-induced insulin resistance serves as another homeostatic 
mechanism to protect the body against weight gain in the face of anabolic pressures, 
including sustained insulin action and leptin resistance.Another long-term mechanism 
leading to reduced insulin action is β-cell failure (331). At first, β cells compensate for 
chronic elevated glucose in the body by elevating insulin secretion in order to maintain 
near-normal blood glucose levels. However, prolonged elevated insulin secretion and 
the toxic effects of ectopic deposition of lipid in pancreatic β cells eventually reduce β-
cell mass until insulin action can no longer maintain near-normal blood glucose levels, 
and decompensation occurs. This progresses to β-cell failure and unstable 
decompensation. When β cells fail, insulin secretion falls while blood glucose remains 
high. β-cell dysfunction results in decreased insulin production and secretion, providing 
another mechanism by which insulin’s anabolic effects are limited during obesity. 
Counterinflammation by IKKε and TBK1  
With chronic insulin desensitization, insulin resistance, and β-cell dysfunction on 




chronic NFκB activity associated with insulin resistance in adipose tissue induces 
negative feedback mediators, such as IKKε and TBK1, to the counter inflammatory 
effects of NFκB-related insulin resistance. Therefore, inflammatory insulin resistance 
may be held in check by the action of counterinflammatory processes by IKKε and 
TBK1 to promote anabolism. 
In chapter 2, we demonstrate that high-fat diet induces adipocyte expression of 
IKKε and TBK1 (288), which counter the action of IKKβ—NFκB signaling (276). In the 
IKKε knockout mice, we saw decreased diet-induced obesity, which was attributed to 
increased energy expenditure. Furthermore, mice lacking IKKε had higher core body 
temperatures and increased adipose UCP1 levels (288). A similar phenotype was 
observed in mice that were administered amlexanox, a selective inhibitor of IKKε and 
TBK1 activity. Mice fed a high-fat diet or leptin-deficient mice had decreased weight 
gain and increased energy expenditure when given amlexanox. Similar to mice lacking 
IKKε, amlexanox administered animals had higher core body temperatures, and higher 
adipose UCP1 levels (292). Inhibitors of IKKε and TBK1 substituted for IBMX in 3T3-L1 
differentiation, which paralleled adipocyte hyperplasia in the IKKε knockout mouse and 
suggested that IKKε and TBK1 may suppress cAMP. 
Interestingly, insulin resistance remains high throughout the pathogenesis of 
obesity, suggesting that counterinflammatory processes may play an anabolic role 
independent of the response to circulating insulin. Through my work, I have established 
an anabolic mechanism that works through a target of insulin signaling, PDE3B, without 
the requirement of circulating insulin or signaling through the insulin receptor. IKKε and 




absence of insulin’s action. In chapter three, I demonstrate that IKKε and TBK1 
phosphorylates and activates PDE3B to decrease cAMP and regulate adipocyte 
metabolism.  
If IKKε and TBK1 desensitize adipose tissue to adrenergic signaling in mouse 
adipose tissue, then their action in human adipose tissue may be the same. Whereas 
humans lose large brown adipose tissue depots early in life, UCP1-laden adipocytes 
with a distinct developmental origin from brown adipose tissue are found in adult white 
adipose depots. It would be interesting to measure IKKε and TBK1 activity in human 
adipose tissue and quantify the amount of brown adipocyte activity is present using PET 
scans. Potentially, these brown-like adipocytes emerge through increased adrenergic 
signaling and increased cAMP load in cells. If IKKε and TBK1 decrease cAMP levels in 
human adipose tissue similar to mouse adipose tissue, then these kinases would 
prevent the emergence of UCP1-laden adipocytes in human adipose tissue and 
decrease energy expenditure. These and other experiments described in this thesis 
collectively suggest that IKKε and TBK1 act outside the central nervous system in 






Feedback control of upstream kinases by IKK family 
members 
Abstract 
The regulation of inflammatory pathways is essential to a coordinated immune 
response. In this study, we reveal a role for IKK family members in downregulating their 
own activity by feedback control on upstream kinases. Inhibition of IKKβ upregulates 
phosphorylation of its own activation loop Ser177/181, indicating negative feedback 
control, and inhibition of IKKε/TBK1 upregulates activation loop Ser172 phosphorylation 
on TBK1 indicating negative feedback control. Both inhibitor-induced activation loop 
phosphorylation events are augmented by treatment with TLR agonists, LPS and 
poly(I:C). TAK1 is required for activation loop phosphorylation of IKKβ in response to 
inflammatory stimuli or IKKβ inhibitor treatment, while another upstream kinase is 
responsible for TBK1 activation loop phosphorylation in response to inflammatory 
stimuli or the IKKε/TBK1 inhibitor. IKKβ phosphorylates TAB1 Thr431 in response to 
inflammatory stimuli. We therefore propose that feedback control of TAK1 by IKKβ 
occurs through phosphorylation of TAB1, and that the IKK family has a conserved 
pattern of negative feedback control of upstream kinases. 





The NFκB family of transcription factors regulate inflammation, along with a 
variety of stress-oriented cellular responses (259). NFκB activity is an important effector 
of inflammatory cell surface receptors, such as Toll-like receptors (TLRs) (260), and 
receptors of proinflammatory cytokines, including TNFα (261). TLRs recognize 
pathogen-associated molecular patterns, such as lipopolysaccharide (LPS) and double 
stranded RNA (dsRNA), which trigger inflammatory signals that orchestrate immune cell 
action to clear microbes from the body (260). Both TLRs and TNFα receptors (TNFRs) 
initiate inflammatory signaling cascades using protein adaptors and polyubiquitin ligases 
that colocalize with these receptors (259). TGFβ activated protein kinase (TAK1) is 
bound by TAK1-binding proteins (TABs), which are phosphorylated in response to 
inflammatory stimuli, and are necessary for TAK1 stability and activity (262-265). TAK1 
activity simultaneously leads to parallel MAPK (p38, JNK) and IKK pathway 
phosphorylation and activation (266). A selective inhibitor, oxozeaenol, was able to 
prevent activation of MAPK and IKK pathways (332). With respect to IKKs, TLR and 
TNFα receptor stimulation leads to receptor interacting protein 1 (RIP1) 
polyubiquitination, which recruits the IKK complex regulatory scaffolding protein NEMO 
to TAB-TAK1, so that TAK1 phosphorylates and activates the IKKβ (267) (268). Active 
IKKβ phosphorylates the inhibitor of κB (IκB), which results in IκB polyubiquitination and 
subsequent degradation through the 26S proteosome (269). The degradation of IκB 
exposes the nuclear translocation sequence of NFκB family members allowing these 
transcription factors to translocate to the nucleus and control the expression of 




The IKK family of proteins is composed of four members: IKKα, IKKβ, IKKε, and 
TANK-binding kinase (TBK1). Similarities and differences have emerged in IKK family 
member function. Whereas IKKα and IKKβ complex with their regulatory subunit NEMO 
to make the canonical heterotrimeric IKK complex, IKKε and TBK1 complex with their 
regulatory subunit TANK to form the noncanonical IKK-related kinase complex (259). 
IKKβ is essential for mediating innate immune responses, including TLR and TNFα 
signaling, while IKKα is more important for regulating adaptive immunity (270). IKKε and 
TBK1, also known as IKK-related kinases, phosphorylate interferon regulatory factors 
(IRFs), which are essential for the expression of type I interferon genes mainly in 
coordinating antiviral responses (272-274).  
The IKK family regulates many facets of immune responses, but kinase 
activation of IKK family members occurs through a conserved mechanism. 
Phosphorylation of activation loop serine residues is important for IKK family kinase 
activation (281). TAK1 phosphorylates IKKβ on activation loop serine 177/181 between 
kinase subdomains VII and VIII leading to IKKβ activation (279). Substitution of alanine 
for serine 177/181 dramatically reduces IKKβ activity, while substitution for 
phosphomimetic glutamate generates a constituitively active kinase (280, 281). 
Phosphorylation of serine 172 on TBK1 and IKKε has been associated with increased 
activity, and serine 172 is required for IKKε/TBK1 activity (282, 283). Therefore, 
regulation of activation loop phosphorylation is indicative of IKK family member activity. 
Several phosphatases are important for the dephosphorylation of the activation loop to 
terminate IKK family member activity (284, 285). However, the mechanisms by which 




p38 phosphorylates TAB1 at Ser423 and Thr431 to downregulate TAK1 activity 
as a mechanism of feedback control to terminate TAK1-dependent p38 signaling (333). 
Since p38 negatively feeds back to downregulate TAK1 activity, we explored the 
possibility that IKK family kinases negatively regulate upstream kinase activity in a 
similar manner. In this study, we reveal a role for IKK family members in downregulating 
their own activity by feedback control on upstream kinases. Inhibition of IKKβ 
upregulates activation loop Ser177/181 phosphorylation indicating negative feedback 
control, and inhibition of IKKε/TBK1 upregulates activation loop Ser172 phosphorylation 
on TBK1 indicating negative feedback control. Both inhibitor-induced activation loop 
phosphorylation events are augmented by treatment with TNFα or TLR agonists, LPS 
and poly(I:C); however, phosphorylation of substrates downstream of IKK family 
members are predictably eliminated. We show that TAK1 is required for activation loop 
phosphorylation of IKKβ in response to inflammatory stimuli and IKKβ inhibitor 
treatment, while an upstream kinase other than TAK1, inhibited by small molecule 
PKC412, is responsible for TBK1 activation loop phosphorylation in response to 
inflammatory stimuli and IKKε/TBK1 inhibitor. Furthermore, we show IKKβ 
phosphorylates TAB1 Thr431 in response to inflammatory stimuli. We therefore propose 
that feedback control of TAK1 by IKKβ occurs through phosphorylation of TAB1, similar 
to negative feedback control of TAK1 by p38, and that the IKK family has a conserved 





Inhibition of IKK Family Members Upregulates Activation Loop Phosphorylation 
Phosphorylation of the IKKβ activation loop was increased by LPS (Figure A.1A) 
and Poly(I:C) (Figure A.1B) in RAW264.7 macrophages. Inhibitors of IKKβ (Compounds 
IV, VII, VIII, PS1145, and BAY) also increased phosphorylation of the IKKβ activation 
loop in the basal state (Figure A.1A,B). Additionally, pretreatment of RAW264.7 cells 
with IKKβ inhibitors followed by stimulation with LPS or Poly(I:C) resulted in augmented 
phosphorylation of IKKβ. IKKβ and IKKα knockout MEFs demonstrate that IKKβ, not 
IKKα, is responsible for phosphorylation of the IKKβ activation loop in response to 
compound VIII (Figure A.1C). IKKε/TBK1 double knockout MEFs treated with TNFα had 
increased IKKβ phosphorylation compared to wild type MEFs, which is consistent with 
IKKε/TBK1 downregulating NFκB activity (data not shown) (276). Phosphorylation of the 
TBK1 activation loop was slightly decreased in response to compound VIII in RAW264.7 
macrophages (data not shown). Phosphorylation of IRF3, a downstream effector of IKKε 
and TBK1, was mildly affected by compound VIII. However, phosphorylation of JNK, a 
downstream effector of TAK1 activity, was augmented by compound VIII when treated 
with LPS and Poly(I:C) (data not shown). The MEK inhibitor, U0126, was able to 
decrease Erk1/2 phosphorylation as previously reported (334); however, U0126 was not 
able to reduce IKKβ phosphorylation (data not shown). 
Phosphorylation of the IKKε and TBK1 activation loops, and activity, were 
previously reported to be induced by LPS and Poly(I:C) (282). In that study, an inhibitor 
of IKKε and TBK1, known as BX795, augmented activation loop phosphorylation in 




regulate their own activity after stimulation. Treatment of RAW264.7 cells with another 
inhibitor of IKKε and TBK1 that is structurally unrelated to BX795, known as CAY 
10576, resulted in increased phosphorylation of the TBK1 activation loop (Figure A.3A), 
which suggested negative feedback by IKKε and TBK1 even in the basal state. TBK1 
activation loop phosphorylation was augmented by LPS and Poly(I:C) after pretreatment 
by CAY10576. Therefore activation loop phosphorylation of both canonical IKKβ and 
noncanonical TBK1 are negatively regulated by their own activity in both the basal and 





Figure A.1 Inhibition of IKKβ upregulates activation loop phosphorylation and is 
augmented by treatment with the TLR agonists A) Western blot of RAW264.7 cells 
treated with IKKβ inhibitors and LPS B) Western blot of RAW264.7 cells treated with 






TAK1 is required for the upregulation of IKKβ activation loop phosphorylation  
Next, we examined the mechanism by which IKKβ negatively regulates its own 
activation loop phosphorylation. Pretreatment of RAW264.7 cells with the TAK1 
inhibitor, oxozeaenol (332), dramatically reduced the phosphorylation of the IKKβ 
activation loop in response to LPS and Poly(I:C) (Figure A.2A), similar to earlier reports 
(332, 335). When oxozeaenol was cotreated with an inhibitor of IKKβ, compound VIII, 
the inhibitor-induced IKKβ activation loop phosphorylation was dramatically reduced 
(Figure A.2B). Therefore, TAK1 was required for increased IKKβ activation loop 
phosphorylation in response to inhibitors of IKKβ, which prevent IKKβ negative 
feedback, as well as inflammatory stimuli. Oxozeaenol treatment also demonstrated that 
TAK1 was required for compound VIII-augmented IKKβ activation loop phosphorylation 
in response to LPS and Poly(I:C) (Figure A.2A). 
TAK1 knockout MEFs were employed to examine the IKKβ negative feedback 
pathway in a TAK1 genetic loss-of-function context (336). The phosphorylation of the 
IKKβ activation loop in response to TNFα and IKKβ inhibitors was reduced in TAK 
knockout MEFs compared to wild-type MEFs, further indicating that TAK1 is required for 






Figure A.2: TAK1 is required (oxozeaenol or TAK1 -/-) for the upregulation of IKKβ 
activation loop phosphorylation in response to agonists and IKKβ inhibitors A) Western 
blot of RAW264.7 cells treated with oxozeaenol, compound VIII, LPS and Poly(I:C) B) 
Western blot of RAW264.7 cells treated with compound VIII, CAY10576, oxozeaenol, 







An Upstream Kinase, not IKKβ nor TAK1, is Required for Upregulation of TBK1 
Activation Loop Phosphorylation 
Previous reports have shown that IKKβ is required for IKKε and TBK1 activation 
loop phosphorylation (276). The CAY10576-induced phosphorylation of the TBK1 
activation loop was not eliminated by pretreatment with the IKKβ inhibitors PS1145, 
compound VIII, or BAY (Figure A.3A). TBK1 phosphorylation was not eliminated by 
oxozeaenol in RAW264.7 cells. Therefore, we performed a kinase inhibitor screen to 
see if any other kinases were required for IKKε/TBK1 negative feedback. Out of 80 
kinase inhibitors used in this screen, PKC412 was the only inhibitor that could 
dramatically reduce CAY10576-induced TBK1 activation loop phosphorylation (data not 
shown).  
Further studies demonstrated that PKC412 could inhibit TBK1 phosphorylation in 
response to CAY10576 and PKC412 could partially inhibit LPS and Poly(I:C) stimulated 
TBK1 activation loop phosphorylation  (Figure A.3B). IRF3 phosphorylation in response 
to LPS and Poly(I:C) was eliminated by PKC412, indicating that PKC412 reduces 
downstream effectors of IKK-related kinase TLR signaling as well. The IC50 of PKC412 
on CAY10576-induced TBK1 phosphorylation was measured at ~300nM (data not 
shown). 
Interestingly, IKKβ activation loop phosphorylation in response to LPS and 
Poly(I:C) was decreased by PKC412 as well, suggesting that PKC412 inhibits a kinase 
upstream of IKKβ as well. PKC412 was not able to inhibit IKKβ inhibitor-induced 
phosphorylation of the IKKβ activation loop. In fact, PKC412 actually augmented 




suggesting that PKC412 inhibits kinases other than TAK1. Therefore, it is likely that 
both the canonical IKKβ and the noncanonical TBK1 pathways are activated by the 
same upstream kinases in response to agonists; however, the negative feedback 






Figure A.3 An Upstream Kinase, not IKKβ nor TAK1, is Required for Upregulation of 
TBK1 Activation Loop Phosphorylation in Response to Inflammatory Stimuli and the 
IKKε/TBK1 inhibitor CAY10576 A) Western blot of RAW264.7 cells treated with 
CAY10576 pretreated with oxozeaenol, IKKβ inhibitors, LPS, or PolyIC B) Western blot 
of RAW264.7 cells pretreated with PKC412 followed by oxozeaenol, IKKβ inhibitors, 




IKKβ Phosphorylates TAB1 and Reduces Kinase Activity of TAK1 
 Feedback control of TAK1 by p38 has been previously reported (333). In that 
study, p38 phosphorylated TAB1 on Thr431, a site that downregulated TAK1 activity. 
We examined whether IKKβ regulates TAK1 through the same mechanism as p38 
through phosphorylation of TAB1 Thr431. Coexpression of IKKβ with the TAB1-TAK1 
complex in Cos cells resulted in a band shift in TAB1 and increased phosphorylation of 
TAB1 Thr431 (Figure A.4). Interestingly, coexpression of IKKβ with TAB1 and wild type 
TAK1 resulted in a band shift of TAK1, and the TAK1 band shift was not observed when 
the TAK1 dead kinase was used, suggesting TAK1 kinase activity is required for further 
phosphorylation by IKKβ. Phosphorylation of TAB1 Thr431 in response to TLR 
stimulation was reduced in RAW264.7 macrophages pretreated with the compound VIII. 
The inhibition of IKKβ decreased phosphorylation of a higher molecular weight version 
of TAB1 (data not shown). 
 Coexpression of IKKβ with the TAB1-TAK1 complex resulted in decreased 
phosphorylation of TAK1 on its activation loop Thr184/187 (Figure A.4). These sites 
were previously reported to be autophosphorylated and responsible for TAK1 activity 







Figure A.4 IKKβ Phosphorylates TAB1 and Reduces Kinase Activity of TAK1. Western 






The experiments performed in this study suggest that IKK family members 
negatively feedback upon upstream kinases of their own activating pathways. IKKε and 
TBK1 have been reported to negatively feedback upon their upstream pathway to 
reduce their own activation loop phosphorylation (282). In that study, macrophages 
treated with an inhibitor of IKK-related kinases augmented activation loop 
phosphorylation when stimulated with LPS or poly(I:C). It has also been reported that 
IKKβ phosphorylates and activates IKKε and TBK1 (276). The mechanism for IKK-
related kinase negative feedback was proposed to occur by IKKε and TBK1 
phosphorylating and inhibiting the canonical IKKβ complex. 
In this study, we show that the IKK-related kinase inhibitor, CAY10576, increases 
TBK1 activation loop phosphorylation both with and without the augmentation of TLR 
agonists LPS and Poly(I:C). Interestingly, we do not see the elimination of TBK1 
phosphorylation in response to CAY10576 after inhibiting IKKβ or TAK1, suggesting that 
IKK-related kinases feedback is mediated by a separate kinase than IKKβ in a separate 
pathway from TAK1. A screen of 80 kinase inhibitors identified PKC412 as a potent 
inhibitor of TBK1 activation loop phosphorylation in response to IKK-related kinase 
inhibitor CAY10576. Studies with PKC412 reveal that it is likely that both the canonical 
IKKβ and the noncanonical TBK1 pathways are activated by similar upstream kinases in 
response to TLR agonists; however, the negative feedback observed by IKKβ and TBK1 
is mediated by different upstream kinase pathways. Previous studies have suggested 





Moreover, no group had previously described negative feedback of IKKβ upon its 
own pathway. In the present study, we show that inhibitors of IKKβ increase IKKβ 
activation loop phosphorylation both with and without the augmentation of inflammatory 
stimuli, LPS or poly(I:C), similar to IKK-related kinases (282). IKKβ inhibitor-induced 
activation loop phosphorylation was eliminated in TAK1 loss-of-function studies using 
the TAK1 inhibitor, oxozeaenol, or TAK1 knockout MEFs. Finally, we demonstrate that 
IKKβ phosphorylates TAB1 on the same site as previously reported for p38 to exert 
negative feedback control on TAK1 autophosphorylation. 
It is important to recognize that several phosphatases are known to 
dephosphorylate IKK family activation loops. Ser/Thr phosphatases are grouped into 
two distinct subfamilies, both of which are important for dephosphorylating Ser177/181.  
From the phosphoprotein phosphatase (PPP) family, PP1 and PP2A have been 
implicated in downregulating IKKβ activity. From the phosphoprotein phosphatase M 
(PPM) family, which require Mn2+/Mg2+ metal ions, PPM1A and PPM1B have been 
implicated in downregulating IKKβ activity (284), and PPM1B negatively regulates 
antiviral response by dephosphorylating TBK1 (285).  TAB1, is a pseudophosphatase 
that has close structural similarity to PPM family phosphatases (286).  
While our studies do not preclude the involvement of phosphatases in regulating 
phosphorylation state, we believe that modulation of upstream inflammatory kinase 
activity serves as an additional feedback mechanism of regulation by IKK family 
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